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ABSTRACT
Molecularly-targeted therapeutics and personalized medicine have dramatically increased
the median survival rate of patients suffering from cancer. However, cellular heterogeneity and the
personalized nature of cancer have resulted in the limited success of single drug treatments which
has led to the use of multiple therapeutic combinations. This has required the development of new
analytical methods capable of multiplexed high-throughput screening (HTS) technologies
necessary to identify is single or multi-agent therapies are effective in ex vivo samples like liquid
biopsies. Droplet microfluidic devices have garnered significant interest to facilitate highthroughput, single cell analysis of heterogeneous populations. However, these devices are still
limited in their ability to assess multiple input conditions such as combinations of multiple drugs
or different doses of the same drug. Moreover, HTS approaches need to be coupled with automated
image analysis metrics capable of rapidly processing raw data and quantifying it in an efficient
manner.
The goal of this work is to address these two areas of need by developing a new method to
track different inputs in a droplet microfluidic trapping array coupled with automated image
analysis of single cell behavior. The first part of this study highlights the use of rare-earth (RE)doped luminescent nanoparticles (NP) as novel method to track input conditions in droplets in a
microfluidic device. The second part of the work deals with the development of an algorithm called
FluoroCellTrack to efficiently analyze single cell data from high-throughput experiments in the
droplet microfluidic trapping array. The β-hexagonal NaYF4 nanoparticles used for droplet
tracking were doped with a rare-earth emitter with unique spectral properties that do not overlap
with established fluorophores like GFP and Rhodamine. In this study, we employed europium as
the dopants which has a luminescence emission spectrum in the red region upon UV excitation.
We demonstrated that the RE-doped nanoparticles are biologically inert and spectrally independent
with common fluorophores and fluorescent stains. This work provided a foundation for future
applications using the combination of NPs and microfluidics for multiplexed droplet tracking to
quantify tumor heterogeneity and assess the effectiveness of combinatorial therapies. To perform
HTS of single cells, a Python algorithm (FluoroCellTrack) was developed to: (i) automatically
distinguish droplets from cells, (ii) count cells in each droplet, (iii) quantify cell viability, and (iv)
identify input conditions using the RE-doped nanoparticles. The performance of FluoroCellTrack
was compared to manual image analysis with a difference in intracellular quantification of ~2%
coupled with a decrease in analysis time of <10 minutes over 20 hours of manual analysis. The
applications for this algorithm are numerous including fluorescence quantification, droplet
barcoding and biomarker detection.
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1. BACKGROUND AND SIGNIFICANCE
1.1 Cancer and the Need for Personalized Medicine
Cancer is one of the leading causes of deaths in the United States with more than 1.6 million
new cases of cancer having been diagnosed this year resulting in over 600,000 deaths per year
during the past decade. This is due to the fact that conventional cancer treatment options including
chemotherapy, hormonal, and antiangiogenic therapies often result in high toxicity and have low
treatment efficacy.[2] For decades, these traditional therapies have not accounted for genetic
variability of individuals and treatment protocols were made based on indirect results of cells at
the population level. In addition, acquired drug resistance due to intratumor heterogeneity further
decreased the efficacy of single-target drug treatment.[2, 3] This led to the development of
combinatorial therapies, wherein multiple oncogenes are targeted simultaneously, resulting in a
more personalized approach to medicine. Personalized medicine is achieved through targeted
therapeutics and pharmacogenomics. Pharmacogenomics deals with the understanding of how a
person’s genes affect the way the body processes and responds to drugs while molecularly-targeted
therapeutics involve the development of drugs towards critical biochemical pathways (like the
ubiquitin-proteasome system, the autophagy lysosome system, and aggresome formation) and
dysregulated enzymes (like kinases and phosphatases).[4] Several drugs like Trastuzumab and
Lapatinib have been used to inhibit protein kinase in breast cancer.[4, 5] Another example is the
development of clinically successful drugs like Bortezomib and Carfilzomib which inhibit
proteasome, an enzymatic complex associated with the ubiquitin-proteasome system (UPS) of
multiple myeloma.[6] There is clinical evidence of a drastic reduction in tumor size in breast cancer
patients when lysosomal-based therapeutics have been coupled with drugs designed to inhibit
deubiquitinating enzyme (DUBs), another enzyme in the UPS, highlighting the merits of
combinatorial therapies.[7] The advantage of combinatorial therapeutics is further validated by
network models which suggest that partial inhibition of a number of different targets is more
effective than complete inhibition of a single target.[5] As a result, the major goal of personalized
medicine is to give cancer patients the treatments that are most likely to work on their cancer with
fewer harmful side effects.
1.2 High-Throughput Microfluidic Devices and Barcoding Technology: A Key Diagnostic
Tool in Cancer
Tumor heterogeneity is defined by the fact that distinct cancer cells within a genetically
identical population can exhibit different morphological and phenotypic profiles like cell
proliferation, metabolism, and death.[4] To fully understand this cell-to-cell variability, a complete
analysis of individual cells across an entire population is critical. Single cell technologies enable
the quantification of the individual cellular response to drugs and the identification of drugresistant subpopulations in a tumor environment which are otherwise lost in population averaged
measurements.[8-10] Conventional methods including single cell PCR quantification and
fluorescent in-situ hybridization (FISH), only provide indirect evidence of protein behavior and
are limited in their need for large sample sizes and their inability to account for tumor
heterogeneity.[10] Existing high-throughput single-cell analysis techniques include mass
cytometry, fluorescent and magnetic activated cell sorting (FACS, MACS) have been widely
adopted in modern labs.[8, 10] However, dynamic cell responses cannot be monitored with these
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techniques, since data are collected at a single time point. Despite the development of these highthroughput single cell analysis tools, a recurring challenge in single cell analysis is to achieve a
precise, sensitive, high-throughput and economic way to detect and analyze a diverse population
of cells.[11] Microfluidics is an emerging solution in addressing these issues by providing low
reagent costs, ease of automation, scalability, room for multi-step integration, improved cell
handling, and dynamic observation.[11, 12] Figure 1.1 shows one of the earliest droplet microfluidic
devices developed by Stephen R. Quake et. al in 2001.[1] Droplet microfluidics is among the most
promising candidates for capturing and processing thousands of individual cells. Droplet based
microfluidic devices uses a 2-phase system, in which each assay is compartmentalized in aqueous
droplets surrounded by an immiscible oil.[13] The advantage of this droplet-based technique is that
it enhances the sensitivity of single cell assays by generating picoliter-sized droplets, thus
localizing single cell studies. These droplet microfluidic devices are also used with fluorescent
barcoding techniques which has led to the creation of a holistic diagnostic system capable of
multiplexed, high-throughput analysis of single cells.[14, 15] One such recent achievement was to
use droplet microfluidic devices in barcoding parallel single DNA molecules.[15] Several barcoding
techniques have been implemented in droplet microfluidic devices including graphic,
spectroscopic, electronic, and physical encoding of the droplets.[16]

Figure 1.1- Vesicle generating microfluidic device.[1] A) Microfabricated channel dimensions at
the point of crossflow B) photomicrograph of the discontinuous water phase introduced into the
continuous oil phase. Dashed rectangle indicates area in photomicrograph.
Recent technologies in micro-scale cancer diagnostics like inDrops is a combination of
spectroscopic barcoding and microfluidic technologies.[17] However, such techniques make use of
expensive antibodies and complex PCR reactions which are time consuming and can require
several steps to generate the barcoding signal. Advances in nanomaterials have produced a new
class of fluorescent labels by conjugating semiconductor quantum dots (QDs) with biorecognition
molecules.[18, 19] These QDs are highly stable to photobleaching, have narrow, symmetric emission
spectra, and size-tunable wavelength.[19] Even though quantum dots offer several advantages over
organic dyes[16], their surface coatings and surface defects can affect the viability of cells.[20] Most
of the existing QD approaches have disadvantages such as lack of flexibility, reaction speed, and
repeatability. Thus, active research is underway to develop a more adaptable, inexpensive, and
viable combination of high-throughput microfluidic and droplet barcoding techniques.
1.3 High-throughput Automated Image Analysis
Microfluidics and droplet barcoding are powerful tools to study and manipulate biological
systems.[11] Droplet microfluidic technologies consisting of micro wells or trapping arrays are
2

capable of segregating and studying single and multiple cells in thousands of parallel
experiments.[13, 15] The increase in such high-throughput cellular studies have generated a need for
rapid, automated screening and analysis tools that are capable of efficient acquisition, processing
and analysis of data. Advancements in digital imaging has made it possible to capture real-time,
dynamic events on micro- and nano-scale levels.[21, 22] But, there is a growing need in the biological
research community for robust and accurate analysis tools to quantitatively measure the intricate
details in these high-throughput experiments.[23, 24] Manual cell counting has been widely used to
quantify fluorescent microscopy data; however, this is a very tedious process and the results can
be highly subjective. Moreover, advanced processing techniques such as pattern recognition and
cell image segmentation must be employed for these biological applications to be quantified.
Several semi-automatic (individual algorithms that can be modified by a user) and automatic
(complete analysis package) platforms have been proposed for image-processing applications in
biomedical research.[22-24] Existing software such as ImageJ[25] and CellProfiler[26] can detect cells,
but are not suitable for automated microwell or array recognition, thus making them incompatible
with droplet trapping or cell encapsulation experiments.[27, 28] CellProfiler segregates cells by “grid
analysis” and ImageJ by macros to defined regions of interest (ROI), but these approaches may
not be suitable to process many images in a high-throughput manner. Proprietary software such as
Genepix and Quantarray allow the user to define individual microwells on an image but they
cannot recognize patterns automatically within the images.[27] Moreover, all of these software
packages are limited to quantify variations in fluorescent intensities and cannot be used to count
cells within droplets or characterize populations of cells based user-defined differences. A
summary of other commonly used software, their features and drawbacks are listed in Table 1.1.[28]
Table 1.1- Publicly available software for biological image analysis
ROI
Required
Tool
Language
Drawbacks
detection
Software
Postgres,
Can only be used in
MATLAB,
PSLID/SLIC
Yes
tomcat
fluorescence microscopy.
C, Python
MATLAB
Cannot count cells.
Does not have automatic pattern
wndchrm
No
None
C
recognition, and ROI detection
This software has an application
Journals,
to count nuclei, but does not
MetaMorph
Yes
C++
VisualBasic
give the number of cells in
individual array spots.
Can give the number of cell
ScanCount,
Yes
MATLAB
MATLAB
colonies automatically, but not
CHiTA
the individual cell numbers.
This software is equipped with
Many
the hardware and to use the
Cellomics
Yes
sophisticated
C, Java etc.,
software, the user needs to use
software
the entire platform.
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1.4 Project Objective
The goal of this project was to combine spectrally independent, biologically benign
inorganic nanoparticles with a droplet microfluidic trapping array to develop a new analytical
droplet trapping technique capable of high-throughput, single cell analysis of combinatorial drug
treatments across a population of cells. In this work, we used europium doped nanoparticles (NPs)
as droplet barcodes. These NPs were synthesized and co-encapsulated with cancer cells within
aqueous microdroplets and screened across the trapping array. This successful proof of concept
showed that these NPs can be potentially employed as spectrally independent luminescent markers
for multiplexed droplet tracking facilitating simultaneous the screening of patient-derived ex vivo
samples in response multiple combinatorial therapeutics.

Figure 1.2 – Rare earth (RE), luminescent particles for high-throughput microfluidic droplet
barcoding. Co-encapsulation of RE-doped nanoparticles with cancer cells and various drug
combinations on a microfluidic droplet trapping array to perform high-throughput screening of
single cells followed by automated analysis of fluorescence microscopy images to obtain
quantified results.
Further, a Python algorithm was developed to analyze microscopy images of cells
encapsulated in droplets trapped in the microfluidic array by (i) automatically distinguishing
droplets from cells, (ii) count cell(s) in each droplet and account for viability (iii) quantify
intracellular fluorescence in each cell and so on. High magnification bright field and fluorescence
microscopy images of these experiments were captured and analyzed with the developed
algorithm. Overall, a novel high-throughput droplet microfluidic barcoding technique and an
algorithm for automated image analysis were developed as shown in Figure 1.2.
1.5 Overview of Thesis
This first chapter introduces the importance of microfluidics and barcoding technologies
as key diagnostic tools of personalized medicine in cancer. It also discusses the problems that exist
with the current approaches to high-throughput single cell analysis, and automated image analysis.
Chapter 2 describes the high-throughput droplet tracking technique with luminescent
nanoparticles in a microfluidic droplet trapping array. This chapter describes the features of the
luminescent nanoparticles, microfluidic device, experiment methodology, qualitative and
quantitative results.
Chapter 3 describes the Python algorithm called FluoroCellTrack that was developed to
process, analyze and extract useful quantitative data from the fluorescent microscopy images.

4

Chapter 4 finally gives the conclusions from this project and recommendations for further
work towards multiplexed droplet barcoding.
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2. HIGH-THROUGHPUT DROPLET TRACKING WITH LUMINESCENT
NANOPARTICLES IN A MICROFLUIDIC DROPLET TRAPPING
ARRAY
2.1 Introduction
Genomic diversity and clonal evolution in cancer has led to substantial intra-tumor
heterogeneity where multiple clonal subpopulations of cancer cells express different properties
including growth rate, immunological characteristics, production and expression of markers etc.[29]
These irregularities manifest diversely despite patients being classified identically due to the
heterogeneity associated with the majority of cancers.[29, 30] Such complex nature of cancer has
resulted in a limited success of single drug treatments leading to the development of combinatorial
therapies, wherein multiple oncogenes are targeted simultaneously, resulting in a push for a more
personalized approach to medicine.[31] One area of personalized medicine is the development of
molecularly-targeted therapeutics towards critical biochemical pathways (like ubiquitin
proteasome system, autophagy lysosome system) and dysregulated enzymes (like kinase).[4]
Several drugs like Trastuzumab and Lapatinib have been used to inhibit protein kinase in breast
cancer.[5] Another example is the development of clinically successful drugs like Bortezomib[32]
and Carfilzomib[33] which inhibit proteasome, an enzyme associated with the ubiquitin proteasome
system (UPS) of multiple myeloma. There is also clinical evidence of drastic reduction in tumor
size with respect to breast cancer, when lysosomal based therapeutics have been coupled with
drugs designed to inhibit deubiquitinating enzyme (DUBs), another enzyme in the UPS,
highlighting the merits of combinatorial therapies.[6, 34] While the implementation of molecularlytargeted therapeutics has improved the prognosis in cancer, the ability to screen patient samples
against molecularly-therapeutics has lagged behind. Techniques to measure drug response in
single, intact cells from a patient biopsy can improve diagnostics by providing direct information
about the effectiveness of the drug target and drug concentration in treating an individual’s
tumor.[35] Conventional methods including single cell PCR quantification and fluorescent in-situ
hybridization (FISH), only provide indirect evidence of protein behavior and are limited in their
need for large sample sizes and their inability to account for tumor heterogeneity.[36] To overcome
this, researchers have developed high-throughput screening (HTS) technologies that are capable
of analyzing a large population of cells in a relatively short period to identify subpopulations of
cells in a heterogeneous sample. These HTS platforms are capable of assessing intact single cells
within patient samples without any complex genetic manipulation of the cells prior to analysis.
Example technologies include fluorescent and associated based cell sorting (FACS, MACS),[8]
capillary electrophoresis[37] and microfluidics[13]. Fluorescent based sorting has traditionally been
used for HTS, but analysis is often limited to cell surface markers and the technology cannot easily
be incorporated into labs and clinics due to size and expense.
Microfluidics offers a significant advantage over competing technologies due to reduced
reagent costs, ease-of-use, significant reproducibility, and compatibility with fluorescent
microscopy.[38, 39] Droplet microfluidic devices exhibit all of these advantages and are capable of
HTS of intact single cells[12] and droplet barcoding for parallel single molecule DNA
6

sequencing[40]. While these microfluidic devices have helped revolutionize cancer screening
techniques, they are still limited in their ability to simultaneously quantify a cellular output (e.g.,
death or intracellular enzyme activity) compared to a specific condition (e.g., concentration or
number of drugs). This is due to the spectral overlap between established fluorescent biomarkers
and droplet barcoding methods resulting in a limited number of simultaneous combinatorial
treatments that can be investigated on a single device. In this work, this limitation is dealt by
combining spectrally independent, biologically benign inorganic nanoparticles with a droplet
trapping array to develop a new analytical technique capable of high-throughput, single cell
analysis of combinatorial drug treatments across a population of cells.
Over the past decade, inorganic luminescent nanoparticles such as quantum dots (QDs)
have been widely used as fluorescent labels among biologists. QDs are endowed with
distinguished characteristics such as small size (10 nm), photostability, narrow emission
bandwidth, single-source excitation, and compatibility for multiplexed detection.[18] However,
since their development in 1998,[41] there have been concerns with their application as probes in
cell imaging, immunoassays, and single molecule detection due toxicity effects and difficult
synthesize procedures.[20] The demand for effective fluorescent labels is still on-going. Another
approach for novel biosensors incorporated rare-earth (RE) doped phosphors. The lanthanide
series contains fifteen elements, lanthanum to lutetium (Z = 57 through 71), which along with
yttrium and scandium, are collectively known as rare earth (RE) elements. A key aspect of Ln(III)
ions as dopants is that, since the 4f sub-shell is well shielded by the 5s and 5p subshells, the energy
of these 4f sub-shells are the least influenced by the surrounding environment which result in welldefined and sharp absorption spectra.[42] This is in fact an attractive property of RE elements over
transition elements, wherein the d-d transitions in the valence d shell of transition metals result in
a spectrum of broadband nature.[43] Additionally, the f energy levels of the RE elements are
conveniently spaced in specific energies, allowing an extended emission spectrum via two
luminescence phenomena: upconversion (high energy to low energy conversion) and
downconversion (low energy to high energy conversion). These different radiative phenomena are
analogous to the anti-Stoke and Stokes shift observed in organic dyes, but with a more prominent
shift of 100’s of nm over 10’s of nm.[44] The upconversion (UC) process is common in fluorescent
bioimaging especially in in vivo studies due to the advantages of IR such as deep tissue penetration,
weak background auto fluorescence, and low photobleaching. Upconversion has several other
applications including photostimulation,[45, 46] to induce cell growth and in optogenetics[46] to
stimulate neurons with near-infrared light. Unfortunately, these applications all require specific
wavelengths that cannot be provided from a single phosphor, necessitating the synthesis of
multiple, carefully designed particles. However, downconversion (DC) luminescence with UV
excitation, offers unique benefits by providing a narrower emission range with ~50 nm windows
for each element. While underutilized in biological applications, this ability to select specific
colors offers an extensive palette for cell identification when performing ex vivo diagnostics.
The work described in this chapter focuses on the use of RE -doped nanoparticles as droplet
trackers using a downconversion fluorescent microscopy platform. Here, two different dopants
(Eu3+, Tb3+) were incorporated into hydrothermally synthesized hexagonal β-NaYF4 nanocrystals.
As a proof of concept, Eu3+-doped nanoparticles were tested here. These NPs, upon UV excitation
have distinct excitation and emission spectra (europium in red) that do not overlap with commonly
used fluorophores and fluorescent stains. The luminescent nanoparticles were characterized for
structure, morphology, spectral properties, and biocompatibility using SEM, XRD, EDX and
7

photoluminescence studies. Next, the RE-doped nanoparticles were encapsulated in picoliter sized
droplets and trapped in a microfluidic droplet trapping array to confirm their potential as spectrally
independent droplet tracker. A series of single cell and NP co-encapsulation experiments were
performed to confirm the spectral independence of Eu3+-doped nanoparticles with green
fluorescent protein (GFP), red fluorescent protein (RFP), and Ethidium Homodimer (EthD-1). The
fluorescent microscopy data from these experiments were processed and analyzed to quantify the
fluorescent signals from NP, fluorophores, and fluorescent stains; highlighting the spectral
independence feature of these luminescent nanoparticles. The spectral independence of RE-doped
NPs was further ascertained using ANOVA F-statistics.
2.2 Materials and Methods
2.2.1 Chemicals
Yttrium(III) nitrate hexahydrate- 99.9% (Rare Earth Oxide - REO), Europium(III) nitrate
hydrate - 99.99% (REO), Terbium(III) nitrate hydrate- 99.9% (REO) were purchased from Alfa
Aesar. Sodium Citrate Dihydrate, ACS; Sodium Fluoride Solid, USP Grade; Hydrochloric Acid
36.5-38.0% ACS were purchased from VWR International.
2.2.2 Synthesis and Characterization of RE-doped Luminescent Nanoparticles
Synthesis: A modified recipe from Li et. al[47] was used to synthesize high quality stable
nanoparticles using a high temperature and high pressure hydrothermal process. In this process,
Y(NO3).6H2O and RE (Eu3+, Tb3+) nitrate were dissolved in 15 mL of water such that the
percentage of RE doping is 2.5 to 10 mol%. To this, 2 mmol of sodium citrate (Na3 citrate = 1:4
molar ratio) and 5 mL of 5M NaF aqueous solution were added. Sodium citrate (RE precursor)
was added as a chelating agent to control the shape and morphology of the nanoparticles. After 10
minutes of vigorous stirring, the pH of the solution was adjusted by adding 1 mL of reagent grade
37% HCl and the hydrothermal reactor was sealed and heated at 180ºC for 3 hours. The reaction
products were washed with DI water and ethanol several times to remove the organic impurities
and neutralize the solution. To facilitate an α to β transition, annealing treatment at 400-600 ºC
was done to achieve the desired morphology. NP with different dopant concentrations were
synthesized by varying the dopant (X3+: Eu3+/Tb3+ concentration during this hydrothermal
synthesis.
Characterization: The synthesized nanoparticles were characterized for structure and
morphology using Powder X-ray Diffraction (XRD) and Scanning Electron Microscopy (SEM).
XRD measurements were performed on an Empyrean PANalytical X-ray diffractometer using Cu
Kα1 (λ=1.54 Å) as radiation source, with a step size of 0.03° in the scanning range of 5º-70º. The
obtained XRD patterns were analyzed using Highscore software for phase identification. SEM
imaging was done using an FEI Quanta 3D FIB microscope operated at 5 kV accelerating voltage.
This instrument was equipped with an EDAX detector which was used to identify the elements
present in the sample. The sample was prepared by casting a drop of the aqueous product on the
double-sided carbon tape attached to the sample holder. All the dried samples were sputtered with
Pt for 4 min to make the sample conducive for the measurements. These nanoparticles were finally
characterized for optical properties using Photoluminescence (PL) studies. An APTI QM-40
spectrofluorometer with a PMT detector and a 75W xenon arc lamp as light source was employed
8

for PL measurements. The scans were performed with a band pass of 2 nm at a scanning rate of 4
nm/s in the range of 450-650 nm upon respective constant UV excitation.
2.2.3 Design and Fabrication of the Microfluidic Droplet Trapping Array
The droplet microfluidic trapping array used in this work is similar in scope to one
previously reported by Safabakhsh et al.[49] The geometry of the device was designed with Autocad
software prior to fabrication. As seen in Figure 2.1.A, the device consisted of two layers: the
bottom main flow channel and the top trapping array (Figure 2.1.B), each having a 40 µm height.
The device had two inlet channels: one for carrier oil (750 μm in diameter) and one for cells/NPs
(470 μm in diameter) which converge at a flow-focusing junction to encapsulate cells and NP in
~180 pL discrete aqueous droplets in a continuous oil phase. Each inlet had a set of microfilters to
prevent any solid residues from clogging the device. The essential component of the bottom layer
(Figure 2.1.C), is the flow focusing junction where both the phases meet for the droplet formation.
After droplet formation, they travel for ~700 µm across a narrow channel before widening and
distributing through the bottom main layer. Serpentine channels were incorporated prior to the
flow-focusing junctions to equalize the pressure for droplet formation at the junction. The
flowrates of each phase play a critical role in the size of droplets. Here, flowrates of 230 µL and
90 μL for the oil and aqueous phases were used to generate droplets of 70 µm diameter. The droplet
trapping array (Figure 2.1.D, E) consisted of a 775-member grid of 70 μm diameter circles
imprinted at a ~40 μm height into the PDMS, to trap the aqueous droplets. The micron scale
channel height and immiscibility of the two phases force the droplets from the oil phase into the
overhead traps. The oil flow was maintained continuously to avoid flushing-out of the trapped
droplets after trapping. Vertical fins were incorporated into the trapping array to increase the
residence time for the potential trapping of these droplets. An outlet port was incorporated at the
end of the flow channel to collect the exit stream.

Figure 2.1- Schematic of the microfluidic droplet trapping array. A) Top view of the device
showing two inlets – one for carrier oil and one for cells and flow-focusing junction in the bottom
layer; trapping array in the top layer. B) Side view illustration of the droplet trapping array C)
Converging of the two fluids at a flow-focusing junction to generate pL-sized droplets. Bright field
D) and fluorescent E) images of GFP-HeLa cells encapsulated in droplets trapped in the array.
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Figure 2.2 – Fabrication of the microfluidic droplet trapping array. A) Soft lithography was used
to fabricate microfluidic patterns on a silicon wafer. B) PDMS replication followed by plasma
bonding and Aquapel treatment was used to create a working microfluidic device
The microfluidic devices were fabricated by a combination of soft lithography and PDMS
replication. The first step was to create the fluidic patterns on a silicon wafer as shown in Figure
2.2.A. The two-step process started with generating the bottom layer consisting of the fluidic
channels using a photoresist polymer (SU-8-2025, Mirochem). The SU-8 was deposited on a clean
silicon wafer and baked at 65°C for 15 minutes followed by a second bake at 95°C for 30 minutes.
After cooling down, the wafer was exposed to UV light with 1.2 mW/cm power intensity for 50
seconds using a photo mask to create the fluidic channels. The wafer was baked again at 95°C post
UV exposure. Following this, a second layer of SU-8 was spun onto the silicon wafer followed by
the same 65°C and 95°C baking steps. The wafer was manually aligned with a second photomask
containing the overhead trapping array followed by UV exposure. Finally, the silicon wafer was
developed with an SU-8 developer solution (Microchem). This step dissolved all of the uncross
linked SU-8 to produce the microfluidic patterns. The wafer was hard baked at 150°C for 30
minutes to increase wafer durability. After cooling down, the wafer was ready for PDMS (poly
dimethyl siloxane) replication. PDMS base was mixed with curing agent (SLYGARD 184 silicone
elastomer kit), in the ratio of 10:1 and degassed in a vacuum chamber to eliminate bubbles formed
when mixing. This degassed PDMS mixture was poured on the fabricated wafer sitting in a petri
dish and was baked for 6 hours at 65°C to cure. Once cured, the PDMS was peeled from the wafer
and the replicas of these microfluidic devices were cut. The device inlet and outlet ports were
punched using a micron-sized hole puncher (a blunted 23G x1 needle). Each PDMS replica was
permanently bonded on a glass slide (Corning Glassware 75x25 mm) using a Harrick Plasma PDC32G basic plasma cleaner. The devices were left overnight to ensure proper bonding between the
PDMS and the glass. The device channels were then made hydrophobic by Aquapel treatment.
Aquapel treatment was essential to prevent channel wetting and the formation of uniform aqueous
phase. Aquapel was manually injected into the device using a filtered syringe with excess Aquapel
flushed out using Novec 7500 oil (3M). The channels were finally dried by blowing nitrogen and
the resultant device as shown in Figure 2.2.B was ready to be used for on-chip experiments.
2.2.4 Cell Culture
MDA-MB-231 cells and RFP expressing MDA-MB-231 cells were a kind gift from Dr.
Elizabeth Martin (LSU). GFP (Green Fluorescent Protein) expressing HeLa cells were a kind gift
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from Dr. Nancy Allbritton (UNC). All cell lines were all maintained in T75 culture flasks. The
MDA-MB-231 cells were cultured in DMEM – Dulbecco’s Modified Eagle Medium with 10%
v/v fetal bovine serum (FBS, Seradigm), 1% MEM Essential Amino Acids (Quality Biological
Inc.), 1% MEM Non-Essential Amino Acids (Quality Biological Inc.), 1 mM Sodium Pyruvate
and 6 µL insulin/500 mL media. The HeLa cells were cultured in DMEM Media with 10% v/v
Calf Bovine Serum. 10X Phosphate-Buffer Saline (PBS: 137 mM NaCl, 10 mM Na2HPO4, 27 mM
KCl, and 1.75 mM KH2PO4 at pH 7.4) and trypsin (Trypsin-EDTA (0.05%) -Thermo Fisher
Scientific) were used during the process of cell culture.
2.2.5 Off-chip Viability Assay
MDA-MB-231 cells were seeded at a density of 1 x 104 cells/mL in 12 well plates and
allowed to incubate for 3 days. On the day of experiment, each well of the 12-well plate was
washed with 1 mL of 1X PBS. 1 mL of a 10 mg/mL nanoparticle slurry in Extra Cellular Buffer
(ECB: 20 mM HEPES, 140 mM NaCl, 5 mM KCl, 1 mM MgCl2.6H2O, 1 mM CaCl2.2H2O, 5 mM
D-Glucose at pH 7.4) was added to each well at one-hour intervals for a 12-hour time period. After
the final time point, the NP slurry was aspirated. It should be noted that, after aspiration of NP
slurry the cells were not washed with PBS to avoid removal of dead cells. 500 µL of reagent stain
mixture (2.5 µM Calcein AM and 4 µM EthD-1 in 1X PBS) was added in each well and incubated
for 20 mins and imaged for viability. Calcein AM and Ethidium Homodimer (EthD-1) are
fluorescence cell viability stains that are based on the simultaneous determination of live and dead
cells. Live cells are distinguished by the presence of intracellular esterase activity, determined by
the enzymatic conversion of virtually non-fluorescent cell-permeant Calcein AM to the intensely
fluorescent calcein. The polyanionic calcein is well retained within live cells producing an intense
green fluorescence in live cells under λex = 485 nm and λem = 515 nm. EthD-1 enters only cells
which have compromised membranes and undergoes a 40-fold increase in fluorescence upon
binding with nucleic acids, thereby producing a bright red signal in dead cells under λex = 525 nm
and λem = 590 nm and thus excluded by the intact plasma membrane of live cells. The experiment
was imaged using a fluorescent DMi8 Inverted Microscope (Leica microsystems). FITC filter set
(λex: 440-520 nm and λem = 497-557 nm) and Rhodamine filter set (λex: 536-556 nm and λem = 545625 nm) were used to excite and capture live/Calcein AM and dead/EthD-1 cells.
2.2.6 Off-chip Fluorescent Microscopy
Next the RE-doped NPs were evaluated for fluorescence using microscopy. A microscopy
imaging chambers was made by binding Silicone O-rings (Ace glass) to microscopy cover slips
(Corning 4x40 mm) using high vacuum grease (Dow Corning. The nanoparticle slurry was made
by weighing and mixing the NP powder in ECB. 200 µL of this slurry was added to the imaging
chambers and imaged using a fluorescent DMi8 Inverted Microscope (Leica microsystems). The
following filter sets (Chroma Tech. Corp) were used for imaging the different nanoparticles: Eu3+
doped NP (λex: 370-420 nm and λem: 605-645 nm); Tb3+ doped NP (λex: 325-355 nm and λem: 505565 nm);
2.2.7 Microfluidic Droplet Tracking using RE-doped Nanoparticles
NPs with different dopant concentrations (e.g., 2.5 and 5 mol% of X3+ in NaYF4) and
different suspension concentrations (5-10 mg/mL) were encapsulated and trapped within ECB
droplets without cells and imaged using a fluorescent DMi8 Inverted microscope (Leica
microsystems). For cell and NP co-encapsulation experiments, the RE-doped nanoparticles were
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co-encapsulated with cells (GFP HeLa cells or RFP MDA-MB-231 cells at a cell density of 6 x106
cell/mL) in aqueous ECB droplets which were then isolated and imaged in the microfluidic droplet
trapping array using a fluorescent DMi8 Inverted microscope (Leica microsystems). The aqueous
phase was the NPs and cells in ECB; the oil phase was Novec 7500 oil with 0.2% Neat 008 fluorosurfactant (Ran Biotechnologies). The fluoro-surfactant was used to stabilize droplet formation
and prevent droplet aggregation. To encapsulate cells with NP in droplets, 4.5 x 106 cells/mL were
supplemented with an NP slurry of 5 mg/mL in ECB. To initiate droplet generation, Tygon tubing
(Cole Palmer) was directly connected to syringes fixed on a dual infusion syringe pump (Harvard
apparatus) and were inserted into the device inlet ports. Different flowrates of 230 µL/hr and 90
µL/hr were used for the oil and aqueous phases. The device was set on the stage of a fluorescent
DMi8 Inverted microscope (Leica microsystems).
To determine if the RE-doped nanoparticles could be encapsulated in droplets with a
population of cells exposed to a standard biochemical assay, a dead stain (Ethidium Homodimer)
was selected. To ensure a population of dead cells MDA-MB-231 cells were binned into two
groups. The first group (live) was resuspended in ECB and incubated at 37°C prior to
encapsulation. The second group (dead) was incubated at 42° C for 1 hour in a heat block to kill
all the cells. These populations of live and dead cells were mixed together with 4 µM EthD-1,
incubated at 37°C for 15-20 minutes, and then injected into the device with the NP slurry.
Qualitative Imaging: Fluorescent DMi8 Inverted microscopy (Leica microsystems) with a digital
CMOS camera C11440 (Himamatsu Photonics K.K.) and software LASX version 3.3.0 were used
to image and analyze these experiments. The following excitation/emission filters (from Chroma
Tech. Corp) were used: FITC filter set (λex: 440-520 nm and λem = 497-557 nm) for GFP;
Rhodamine filter set (λex: 536-556 nm and λem = 545-625 nm) for RFP, EthD-1; Eu3+ doped NP
(λex: 370-420 nm and λem: 605-645 nm); and Tb3+ doped NP (λex: 325-355 nm and λem: 505-565
nm).
Quantitative Analysis: Manual sorting was performed to categorize different droplet
subpopulations and to obtain information on droplet trapping, single and multiple cell
encapsulation, cell and NP co-encapsulation efficiencies. A sample analysis was done in triplicate.
A manual line scan region of interest (ROI) was drawn across droplets containing both cells and
NPs to quantify their fluorescent signal as well as their signal-to-noise ratio values (S: N). These
values were normalized and was plotted using Origin (OriginLab Corp.).
Normalized Fluorescent Signal =

𝑋−µ

[Eq 2.1]

𝜎

Equation 2.1 was used to calculate a normalized fluorescence where X is the fluorescent signal of
cell or NP, µ is the mean fluorescent signal, and σ is the standard deviation in the fluorescent
signal. Statistical analysis of spectral independence was performed using analysis of variance
(ANOVA) Hypotheses Tests or F-Tests using SAS Software. In order to statistically assess the
spectral independence of NP from cells the normalized average of the S: N ratio of the NP obtained
from the desired filter set was compared against its normalized average S: N ratio from other filter
sets and was assessed by statistical t-test. The resulting p-values from these tests were reported.
Similarly, spectral independence of cells (e.g, GFP-HeLa, RFP-MDA-MB-231, and MDA-MB231 cells stained with EthD-1) were also assessed by similar statistical analyses. A sample size of
n= 35 droplets was considered for these ANOVA F-Tests.
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2.3 Results and Discussion
2.3.1 Synthesis of Hexagonal β-NaYF4 Nanoparticles for Downconversion Applications
The RE-doped nanoparticles were characterized using Scanning Electron Microscopy
(SEM), X-Ray Diffraction (XRD) and Electron Dispersive X-Ray Spectroscopy (EDX) in order
to ensure the correct structure, morphology and purity. All NP synthesis and characterization was
performed by Khashayar R. Bajgiran, a collaborator on this project. The RE-doped luminescent
nanoparticles were also successfully characterized using photoluminescence (PL) tests to confirm
proper downconversion. The SEM results from Figure 2.3.A show the formation of uniform,
monodisperse, hexagonal NaYF4 nanoparticles, of 400 nm in length and 150 nm in diameter. The
diameter and length of these particles were controlled by varying the RE: citrate concentration up
to 1:8 with a 1:1 ratio to produce nanoparticles with diameters of 150-500 nm and greater than 400
nm long. Additionally, the crystal structure was characterized via X-Ray Diffraction (XRD). The
XRD scan in Figure 2.3.B resulted in diffraction peaks which were indexed to the β-NaYF4 crystal
structure (JCPDS #17-6069), indicating that no other impurity phase is formed. Electrondispersive X-Ray Spectroscopy (EDX) measurements confirmed that the particles were pure
NaYF4.

Figure 2.3- Characterization of RE-doped nanoparticles. The SEM image shows hexagonal
nanoparticles roughly 150 nm in diameter and 400 nm in length. (B) The XRD scan is indexed to
the β-NaYF4 crystal structure (JCPDS #17-6069) without the presence of contaminates based on
(C) EDX fluorescence. (D) Photoluminescence of Eu3+ doped NaYF4 nanoparticles demonstrate
the characteristic Eu emission peaks when excited with 397 nm light.
As it can be seen from Figure 2.3.C, all crystals exhibited 𝐾𝛼 emission lines at 0.677 keV
and 1.040 keV, along with 𝐿𝛼 emission line at 1.924 keV which were standard emission lines for
Fluorine, Sodium, and Yttrium atoms respectively. Since the concentrations of RE dopants in the
crystal structures were small, EDX results were magnified by a factor of 10 to illustrate the
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presence of each dopant in the crystal lattice. The 𝐿𝛼 and 𝐿𝛽 emission lines at 5.817 and 6.456
keV, 6.238 and 6.978 keV, 6.458 and 7.248 keV were assigned to Europium and Terbium,
respectively. Si and Pt peaks were observed due to sample processing. Finally, downconversion
photoluminescence tests were done to these RE-doped luminescent nanoparticles. As a result,
room-temperature downconversion luminescence spectra of NaYF4:Ln3+ (Ln3+: Eu3+ and Tb3+)
were observed with the excitation wavelength of 397 nm for Eu3+ and 350 nm for Tb3+ (Figure
2.3.D). For Eu3+, the 5D0 → 7F2 transition peak at 617 nm (red) was chosen for detection with 605645 nm window filter-set. Similarly, for Tb3+, the peaks at 543 nm (green) were chosen for
detection in the 505-565 nm filter-sets respectively. Thus, RE doped nanoparticles with desired
structure, morphology and optical properties were successfully synthesized and characterized.
2.3.2 RE-doped Luminescent Nanoparticles are Biocompatible and Non-toxic in a Model
Cancer Cell Line
The biocompatibility of the RE-doped NPs was performed again the triple negative breast
cancer cell line MDA-MB-231. The off-chip viability tests confirmed that the RE-doped
nanoparticles were biologically inert to the cells even after an incubation period of 12 hours (Figure
2.4). It was essential for the RE-doped phosphors to have no effect on the cellular viability if they
were to be encapsulated with cancer cells in microfluidic droplets. Both live and dead MDA-MB231 cells were imaged in the presence of Eu3+ doped nanoparticles. As expected, the nanoparticles
did not induce any cell death in the population of MDA-MB-231 cells over the course of 12-hour
experiment as indicated by the lack of red cells in the right most column of Figure 2.4. A similar
result was obtained in a control experiments in the absence of nanoparticles. This data showed that
the RE-doped nanoparticles are non-toxic to cancer cells and can be successfully encapsulated
with cancer cells in microfluidic droplets.

Figure 2.4- The impact of the RE-doped luminescent nanoparticles on cellular viability. Eu3+doped NaYF4 nanoparticles were incubated with MDA-MB-231 cells at 37°C at 4 h (top row) and
12 h (bottom row) followed by live/dead staining using Calcein AM (green, middle column) and
EthD-1 (red, right column). Scale bar is 150 µm.
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2.3.3 RE-doped Luminescent Nanoparticles can be Detected using Fluorescent Microscopy
The downconversion process in the NPs was observed using fluorescent microscopy with
a similar approach to that of the photoluminescence tests described above. First, the correct
excitation and emission filters (Chroma Tech. Corp) were selected to collect he optimal excitation/
emission range of the RE-doped nanoparticles. The Eu3+ doped NP, when excited with a UV source
(λex: 370-420 nm) luminesced in the red region which was captured by the emission filter (λem:
605-645 nm). This can be seen in Figure 2.5.A and B, where the Eu3+ doped NP showed red
luminescence upon UV excitation. Similarly, Tb3+ -doped NPs luminesced in the green regions
upon UV excitation (data not shown). These results coincided with the previously discussed
photoluminescence studies and validated that RE-doped nanoparticles can be visualized using
fluorescent microscopy.

Figure 2.5 - Microscopy image of Eu3+ -doped NP. Bright field A) and fluorescent B) images of
the NP aggregate under 20X magnification. Transition peak 617 nm (red luminescence) of Eu3+ doped NP captured by emission filter λem: 605-645 nm when excited by UV source λex: 370-420
nm.
2.3.4 Successful Encapsulation of RE-doped Nanoparticles and Droplet Tracking in
Microfluidic Trapping Array
Once it was confirmed that the RE-doped NPs could be detected by fluorescent
microscopy, the next step was to assess their ability to be used as droplet trackers in the
microfluidic droplet trapping array. This was performed by conducting experiments encapsulating
RE-doped nanoparticles in aqueous ECB droplets in the absence of cells. The NP-containing
droplets were trapped and imaged with the findings from the Eu3+-doped NP encapsulation studies
discussed here. As seen from Figure 2.6, stable droplets encapsulating nanoparticles were
generated and trapped using the microfluidic device. Different NP suspension concentrations (5
mg/mL and 10 mg/mL) were successfully encapsulated in the device. A 5 mg/mL NP slurry
resulted in the nanoparticles forming small aggregates having a non-uniform distribution across
the droplet. A NP slurry of 10 mg/mL showed a significant nanoparticle aggregation along the
periphery of the droplets, unlike the suspension concentration of 5 mg/mL. Additionally, NPs with
different dopant concentrations (Eu3+:2.5 mol% and 5 mol%) were used in nanoparticle
encapsulation experiments (data not shown). However, the difference in dopant concentration did
not have a significant difference in fluorescent intensity from NP within droplets (described in
Table 2.1) thus, only 2.5 mol% dopant concentration was used for the remainder of the studies.
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Figure 2.6 –RE-doped NPs encapsulated in aqueous droplets in a microfluidic device. Different
concentrations of NPs were injected into the device: 5 mg/mL (top row) and 10 mg/mL (bottom
row). The NPs formed small aggregates across the droplet for 5 mg/mL NP slurry but aggregated
along the periphery of the droplet for 10 mg/mL suspension. Scale bar is 35 µm.
Once NP encapsulation was confirmed in the droplet microfluidic device, the next step was
to confirm their ability as droplet trackers. A potential application of the RE-doped nanoparticles
was to track droplets containing single cancer cells. It is important to note that the NPs are not
barcoding individual droplets (and hence individual cells), but are more useful to track different
inlet conditions. For example, a population of cells challenged with a specific dose of a
chemotherapeutic (e.g., concentration or number of drugs). To explore the ability of the RE-doped
NPs as droplet trackers, cell and NP co-encapsulation experiments were performed. Eu3+-doped
nanoparticles were co-encapsulated with GFP-expressing HeLa cells to confirm that the cells and
NPs exhibited distinct, independent fluorescent spectra. As expected, there was no overlap in
emission spectra between the Eu3+-doped NP and the GFP HeLa resulting in two separate, easily
visualized fluorescent signals (Figure 2.7). Interestingly, sometimes the nanoparticles were
observed to aggregate around the cells in addition to non-uniform distributions across the droplets.
These results are shown in Figure 2.7 and were also successfully repeated with RFP-expressing
MDA-MB-231 cells expressing red fluorescent protein (data not shown). Next, this analysis was
extended to determine if the RE-doped nanoparticles could be encapsulated in droplets with a
population of both live and dead cells. To accomplish this, the mixed population was stained with
EthD-1 (red cells = dead) and co-encapsulated with Eu3+-doped nanoparticles in the microfluidic
device. As seen in Figure 2.8, the microfluidic trapping array was easily able to separate and
identify live and dead cells. In some cases, the NPs would aggregate on top of dead cells and which
resulted in a slight ambiguity to distinguish a dead cell from within a layer of nanoparticle
aggregate. However, the fact that the nanoparticles would aggregate at many different spots across
droplets was used to address this issue. The nanoparticles that aggregated away from the dead cell
were used to confirm the spectral independence of Eu3+-doped NP from EthD-1. Fortunately, this
issue only occurred in ~1% of the cells. It was discovered that the Eu3+-doped NP did not show up
in the filters that were used to capture Tb3+-doped NPs, highlighting the potential of RE-doped
nanoparticles to track cells within droplets on a multiplexed microfluidic trapping array platform.
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Figure 2.7 - 5 mg/mL Eu3+-doped NaY4 nanoparticles co-encapsulated with GFP-expressing HeLa
cells. Brightfield (upper left), 492/514 nm excitation/emission (upper right), 395/620 nm
excitation/emission (lower left), and overlay (lower right) images. * denotes NPs and # denotes
GFP-HeLa cell across the droplet.

Figure 2.8 – Spectral independence of EthD-1 (dead stain) with nanoparticles. A mixed population
of live and dead MDA-MB-231 cells was co-encapsulated in aqueous droplets along with 5 mg/mL
Eu3+-doped nanoparticles. Dead cells are shown in red due to EthD-1 uptake and live cells
remained colorless. Brightfield (upper left) image. No overlap in emission spectra was observed
between EthD-1 (upper right) nanoparticles (lower left). Overlay image (lower right) highlighting
different subpopulations – magenta box showing droplet with just NP, red box showing dead cell
with NP, green box showing live cell with NP. Note: Nanoparticles are depicted in magenta to
distinguish from the dead stain (red).
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2.3.5 Quantification and Confirmation of Spectral Independence between Biochemical
Stains and Eu3+-doped Nanoparticles
Up until now all of the reported results have been qualitatively evaluated by visual
inspection of the cells and NPs within the aqueous droplets. In effort to confirm the signals
observed are distinct and reproducible, quantitative analysis was performed with the cells and NPs
across the different filter sets.
Manual sorting to categorize different droplet sub-populations
Single cells are distributed within the aqueous droplets following a Poisson distribution
with a typical single cell encapsulation rate of ~40% of the droplets. Next, the distribution of both
NPs and cells within the droplets was investigated to determine the statistics of how both species
separated across the population of trapped droplets. Five scenarios were identified and assessed
across the entire array: (1) droplets with nanoparticle aggregates, (2) droplets with cells, (3)
droplets with NPs and a cell (distinct ROI), (4) droplets with NPs on top of cells (indistinct ROI),
and (5) empty droplets. Such diverse droplet subpopulations were generated due to the random
nature of how both species interact during droplet generation as a result of inability to control the
presence of nanoparticles/cells within droplets, or to decide the position of nanoparticles/cells
within droplets. A sorting analysis was performed to identify the percentages of each
subpopulations in addition to identifying single/multiple cell encapsulation efficiency, NP tracking
efficiency and also the ability to distinguish spectral features of NP and cells
(fluorophore/fluorescent stain). A sample analysis from GFP HeLa cell and Eu3+ doped
nanoparticle co-encapsulation experiments with a sample size of n=2200 droplets yields ~6%
empty droplets, ~43% droplets with just NP and ~51% droplets with cells and NP (Figure 2.9).

Figure 2.9 – Different subpopulations achieved within droplets during NP and cell coencapsulation experiments. A) Percentage of each sub-population (n = 2200 droplets) i) empty
droplet ii) droplet with just NP iii) droplet with just cell iv) droplet with NP and cell v) droplet
with NP around cells vi) droplet with multiple cells. B) Image of each of the five subpopulations
described in (A)
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Effect of dopant and suspension concentration in NP encapsulation experiments
In order to identify optimal NP loading conditions within the aqueous droplets, several
variables were evaluated including dopant concentration and NP slurry concentration. Results
from Eu3+-doped NPs encapsulated in droplets are presented in Figures 2.10 to 2.12. First, it was
discovered the dopant concentrations of 2.5 mol % and 5 mol % did not have a significant effect
on NP fluorescent signal. Interestingly, these results did not conform with the photoluminescence
test as shown in Figure 2.11. This could be due to the fact of exciting a single NP aggregate in a
picoliter sized droplet in the microfluidic device provides a different environment when compared
to exciting a highly concentrated NP slurry during off-chip photoluminescence tests. Next, the
effect of NP slurry concentration was assessed in the aqueous droplets. As shown in Figure 2.12.A,
B, the nanoparticles aggregated along the periphery of the droplet for a 10 mg/mL Eu3+ NP slurry.
A comparison was made with an ECB control droplet with no NPs and a 5 mg/mL Eu3+ NP slurry
(Figure 2.10) to confirm that the two peaks in Europium filter observed at the periphery of the
droplet were due to the accumulation of NP along the interface of droplets. However, for a 10
mg/mL NP suspension, the inability to control NP concentration within each droplet led to a highly
variable system which resulted in inconsistency with NP accumulation across the droplet
periphery. Thus, a 5 mg/mL NP suspension with a dopant concentration of 2.5 mol% was observed
to be the optimal conditions to provide the desired fluorescent signal from the NPs. The average
normalized S: N ratio value of NP from each of the fluorescent channels for the above cases are
shown in Tables 2.1 and 2.2. A sample size of n=320 droplets was used for each case. These
numerical values conformed with the graphical explanation and thus, showed the spectral
independence of Eu3+ -doped NP from other filter sets used in this study.

Figure 2.10 – Effect of dopant concentration on NP fluorescent signal in aqueous droplets A) 5
mg/mL, 2.5 mol% Eu3+-doped NPs in ECB droplets. Line scan ROI across droplet showing the
signal intensity from NP along the distance of the line. B) 5 mg/mL, 5 mol% Eu3+-doped NPs in
ECB droplets and respective line scan showing the signal intensity from NP across the distance of
the line. * denotes the NP and its corresponding signal intensity across the droplet. Scale bar is 35
µm.
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Figure 2.11 – Downconversion photoluminescence of 5 mg/mL Eu3+-doped NPs and the effect of
dopant (Eu) concentration in emission peak intensity. A) Excitation wavelength of 397 nm for Eu:
X mol%-doped NaYF4. B) Higher intensity in emission peak of 5 mol% Eu (in red) over 2.5 mol%
Eu (grey).
Table 2.1- Effect of dopant concentration on NP fluorescent signal. Line scan ROI across droplets
giving average normalized S: N ratio value of Eu3+ doped NPs. Analysis confirmed spectral
independence of Eu3+-doped NPs with other filter sets used in this study.
ROI
FITC
Rhodamine
Europium
Terbium
Case
Category
(µm)
filter
filter
filter
filter
NP
45-60
1.03
1.11
3.16
1.20
Figure
2.10.A
Cell
NP
40-60
1.13
1.08
3.86
1.18
Figure
2.10.B
Cell
-

Figure 2.12 - Effect of NP slurry concentration on fluorescent signal and distribution. (A) Control
ECB droplet alone with no NPs. Line scan across droplet showing no significant peaks denoting
absence of NP inside droplet. B) Eu3+-doped NPs (10 mg/mL) encapsulated in ECB droplets. Line
scan having two peaks confirming accumulation of NP along the interface. * denotes the NP and
its corresponding signal intensity across the droplet. Data is representative of ~320 droplets. Scale
bar is 35 µm.
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Table 2.2- Effect of Eu3+-doped NP slurry concentration on fluorescent signal. Average
normalized S: N ratio value of Eu3+ doped NPs and their spectral independence with other filter
sets used in this study.
FITC
Rhodamine
Europium
Terbium
Case
Category ROI (µm)
filter
filter
filter
filter
NP
1.12
1.09
1.42
1.3
Figure
2.12.A
Cell
60-70;
NP
1.26
1.04
4.63
1.05
Figure
130-140
2.12.B
Cell
Eu3+ -doped NPs are spectrally independent from green fluorescent protein (GFP HeLa cell)
In order to quantify the spectral independence of Eu3+-doped NP with GFP, Eu3+-doped
NPs and GFP-expressing HeLa cells were co-encapsulation in the microfluidic device. A few
example cases were considered as shown in Figure 2.13. As seen in Figure 2.13.A, a droplet
containing a GFP-HeLa cell gave distinct signal from its filter. In Figure 2.13.B, a droplet
containing both Eu3+-doped NPs and a GFP-HeLa cells at different positions resulted in
distinguished signals in the respective filter sets. In case of Figure 2.13.C, the Eu3+-doped NPs
formed a layer around the GFP-HeLa cells giving raise to overlapping signals at that ROI position.
This occurred in ~1% of the total population. In some cases, despite this overlap, there was a NP
aggregate elsewhere in the droplet giving rise to a small peak in the Europium filter set at a
different ROI position clearly showing that the droplet was tracked by the Eu3+-doped NPs. Table
2.3 shows the numerical correlation of these results in terms of the S: N ratio values. A sample
size of n=35 droplets was used for each case.
Table 2.3- Spectral independence of Eu3+ doped NP with green fluorescence protein (GFP).
Average normalized S: N ratio value of Eu3+ doped NPs, GFP-HeLa cells and their spectral
independence within their detection filters and other commonly used filter sets.
ROI
FITC
Rhodamine
Europium
Terbium
Case
Category
(µm)
filter
filter
filter
filter
NP
Figure
2.13.A
Cell
50-70
6.54
1.21
1.01
1.69
NP
37.5-52
1.18
1.05
5.56
1.15
Figure
2.13.B
Cell
50-70
4.78
1.09
0.99
1.68
Figure
NP and
75-100
4.36
1.01
4.82
1.43
2.13.C
cell
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Figure 2.13 – Spectral independence of Eu3+-doped NPs compared to GFP-expressing HeLa cells
A) GFP-HeLa cell encapsulated in ECB droplet without NPs. Line scan across droplet showing a
significant signal from the cell. B) Eu3+-doped NPs co-encapsulated with a GFP-HeLa cell. Line
scan having distinguished signals at different line ROI from respective filters confirm the presence
of NPs and cell at different spots inside droplet. C) Example of NPs around a cell. The fluorescent
signal from NPs and the GFP-HeLa cell was distinguished using the respective filters along the
same line ROI denoting the presence of NP and GFP-HeLa cell at the same spot. * denotes NPs
and # denotes GFP-HeLa cell and their corresponding signal intensities across the droplet. Scale
bar is 35 µm.
Eu3+ -doped NP is spectrally independent with red fluorescent protein (RFP MDA-MB-231 cell)
A similar analysis was performed as described above but now with RFP-expressing MDAMB-231 cells to confirm the spectral independence of Eu3+-doped NP and RFP. Similar to the
results discussed in the previous section, Figure 2.14 consists of an example droplet from each
case. The RFP MDA-MB-231 cell gave a distinguished signal in its corresponding filter sets
(Rhodamine) as shown in Figure 2.14.A. Cases like in Figure 2.14.B, where the cell and Eu3+doped NP aggregate were at different positions inside a droplet, led to distinct ROI positions
contributing to clearly defined fluorescent signals. In some cases, the Eu3+-doped NP formed a
layer around the cell which gave rise to distinct signals (Figure 2.14.C). The S: N ratio values for
each of these cases corresponding to the respective fluorescent channels as shown in Table 2.4
highlight the spectral independence of Eu3+-doped NPs from red fluorescent protein (RFP). A
sample size of n=35 droplets was used for each case.
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Table 2.4 - Spectral independence of Eu3+-doped NPs from red fluorescence protein (RFP).
Average normalized S: N ratio value of Eu3+-doped NPs, RFP-expressing MDA-MB-231 cells and
their spectral independence with their detection filters and other commonly used filter sets.
FITC
Rhodamine
Europium
Terbium
Case
Category ROI (µm)
filter
filter
filter
filter
NP
Figure
2.14.A
Cell
60-75
1.10
5.32
1.43
1.11
NP
30-50
1.02
1.34
5.21
1.09
Figure
2.14.B
Cell
75-95
1.14
3.97
1.36
1.11
37-45;55NP
1.19
1.03
5.98;5.81
1.36
70
Figure
2.14.C
Cell
45-60
1.23
4.68
1.31
1.09

Figure 2.14 - Spectral independence of Eu3+-doped NPs from RFP-expressing MDA-MB-231
cells. A) A cell encapsulated in a droplet without NPs. Line scan across droplet showing a
significant signal from the cell. B) Eu3+-doped NPs co-encapsulated with an RFP-MDA-MB-231
cell. Line scan having distinguished signals at different line ROI from respective filters confirm
the presence of NP and cell at different spots inside droplet. C) Instance of NPs aggregating around
a cell. Distinguished signals from the NPs and the cell were observed from respective filters. *
denotes NPs and # denotes RFP-expressing MDA-MB-231 cells and their corresponding signal
intensities across the droplet. Scale bar is 35 µm.
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Eu3+ -doped NP is spectrally independent with Ethidium Homodimer (dead cell)
A similar analysis was then performed using the common dead stain Ethidium Homodimer.
A population of live and dead MDA-MB-231 cells were stained with EthD-1 and co-encapsulated
with Eu3+-doped NPs inside droplets. The resulting droplets consisted of 8 subpopulations:
droplets with 1) just NPs 2) live cell(s), 3) dead cell(s) 4) live cell(s) with NPs (-distinct ROI), 5)
dead cell(s) with NPs (distinct ROI), 6) live cell(s) with NPs (indistinct ROI), 7) dead cell(s) with
NPs (indistinct ROI), and 8) a combination of live and dead cells inside the same droplet. The
above cases are discussed in Figure 2.15, showing the ROI position of cell and NP with their
corresponding fluorescent signals. The first five subpopulations are easy to quantify with distinct
S: N ratio values from the cell or NPs (Figures 2.15.A, C). The live cells in subpopulation 6 would
not contribute to any fluorescent signal due to the absence of EthD-1 uptake– (Figure 2.15.B).
Thus, this subpopulation gives a distinct signal only from Eu3+-doped NPs. Droplets from case 7
(Figure 2.15.D) with overlapping fluorescent signals from the cell and NPs (which contribute to
about 1% of the total population) were ignored. Subpopulation 8 is a complex system having a
combination of live and dead cells which might or might not have overlapping signals. Such
systems were neglected from the analysis due to the inability to distinguish if the cell was alive or
dead. The average normalized S: N ratio values of the above cases is shown in Table 2.5 describing
the subpopulations with live and dead cells. Each table shows the spectral independence property
of Eu3+-doped NP with EthD-1 and the ability to quantify data even with complex droplet
subpopulations.
Table 2.5 - Spectral independence of Eu3+ doped NP with live MDA-MB-231 cells (No EthD-1
uptake) and dead MDA-MB-231 cells (EthD-1 uptake). No signal from live cells and fluorescent
signal in rhodamine filter from dead cells; average normalized S: N ratio value of Eu3+ doped NP
and its spectral independence with its detection filter and other commonly used filters.

65-72

FITC
filter
1.02

Rhodamine
filter
1.14

Europium
filter
1.07

Terbium
filter
1.19

52-70

1.10

1.27

4.37

1.21

45-60
14-30
37-50;75-90
75-90

1.03
1.12
1.12
1.26

1.12
5.23
1.17
7.89

4.57
1.17
3.28;7.03
1.54

1.01
1.05
1.16
1.39

Case

Category

ROI (µm)

Figure
2.15.A
Figure
2.15.B
Figure
2.15.C
Figure
2.15.D

NP
Cell
NP and
cell
NP
Cell
NP
Cell
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Figure 2.15 - Spectral independence of Eu3+-doped NP with EthD-1-stained cells. A) Live cell
encapsulated in a droplet. Line scan across droplet showing absence of NP. B) Eu3+-doped NP coencapsulated with a live cell. Line scan having distinguished signal in Europium filter confirming
the presence of NP. No signal from Rhodamine filter showing the presence of live cell due to its
inability to intake EthD-1. C) Example of NPs aggregating around the cell with distinguished
signals from NPs and the cell from their respective filters. D) NP around cell giving distinguished
signals from respective filters along the same and different line ROI distance giving overlapping
signals in the former case but distinct signals in the latter case. * denotes NPs and # denotes dead
cell (EthD-1) and their corresponding signal intensities across the droplet. Scale bar is 35 µm.
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Statistical assessment of spectral independence of Eu3+-doped NPs using ANOVA F-Tests
The average normalized S: N ratio values obtained for Eu3+-doped NPs, GFP-expressing
HeLa cells, RFP-expressing MDA-MB-231 cells, and EthD-1-stained MDA-MB-231 cells from
the above experiments were further analyzed to confirm the results were statistically significant to
confirm spectral independence. Spectral independence data from each of the above discussed
experiments were considered. ANOVA hypotheses tests considering null hypotheses and alternate
hypotheses for different cases are shown in Tables 2.6, 2.7, 2.8. P-values greater than 0.05 favor
the null hypotheses while p-values smaller than 0.05 rejects the null hypotheses favoring the
alternate hypotheses. Thus, the resulting p-values from Tables 2.7, 2.8, 2.9 show strong evidence
for the null hypotheses proving the rightness of the quantified spectral independence of Eu3+-doped
NP with GFP, RFP and EthD-1. A sample size of n=35 droplets was used. Such statistical evidence
was very useful when threshold values of average S: N values had to be fixed for automating this
quantification (see Chapter 3).
Table 2.6 – ANOVA F-statistics for analysis of threshold values of average normalized S:N ratio
values of Eu3+-doped NP and GFP-expressing HeLa cells. Null hypotheses: 3<µ(S:N)<7.5;
3<µ(S:N)<10; µ(S:N)<2.5 for respective cases. ‘µ(S:N)’ denotes mean normalized S:N ratio values (i.e.
the average normalized S:N ratio values fall within the range). Alternate hypotheses: The average
S: N ratio values do not fall within the given range. P value <0.05 rejects the null hypothesis in
favor of the alternate, whereas larger p values fail to reject the null hypotheses.
Average normalized
Normalized S:N ratio value Null
pCases
S:N ratio value (AU)
Standard Deviation (AU)
Hypothesis
value
Eu3+ doped
4.34 (Europium filter)
1.26
3<µ(S:N)<7.5 >0.05
NP
1.06 (FITC filter)
0.59
µ(S:N)<2.5
>0.05
5.86 (FITC filter)
2.22
3<µ(S:N)<10 >0.05
GFP - HeLa
1.22 (Europium Filter)
0.67
µ(S:N)<2.5
>0.05
Other filters
Terbium
1.43
0.35
µ(S:N)<2.5
>0.05
filter
Rhodamine
0.98
0.45
µ(S:N)<2.5
>0.05
filter
Table 2.7 – ANOVA F-statistics for analysis of threshold values of average normalized S:N ratio
values of Eu3+-doped NPs and RFP-expressing MDA-MB-231 cells. Null hypotheses:
3<µ(S:N)<7.5; 3<µ(S:N)<10; µ(S:N)<2.5 for respective cases. ‘µ(S:N)’ denotes mean normalized S:N
ratio values (i.e. the average normalized S:N ratio values fall within the range). Alternate
hypotheses: The average S: N ratio values do not fall within the given range. P value <0.05 rejects
the null hypothesis in favor of the alternate, whereas larger p values fail to reject the null
hypotheses.
Cases

Average normalized
S:N ratio value (AU)

Normalized S:N ratio value
- Standard Deviation (AU)

Null
Hypothesis

pvalue

Eu3+ doped
NP

4.34 (Europium filter)
1.24 (Rhodamine filter)

1.26
0.83

3<µ(S:N)<7.5
µ(S:N)<2.5

>0.05
>0.05
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RFP-MDAMB-231

5.41 (Rhodamine filter)
1.76 (Europium filter)

1.89
0.57

3< µ(S:N)<10
µ(S:N)<2.5

>0.05
>0.05

1.28

0.33

µ(S:N)<2.5

>0.05

1.11

0.42

µ(S:N)<2.5

>0.05

Other filters
Terbium
filter
FITC
filter

Table 2.8 – ANOVA F-statistics for analysis of threshold values of average normalized S:N ratio
values of Eu3+-doped NPs and dead MDA-MB-231 cells (EthD-1-stained). Null hypotheses:
3<µ(S:N)<7.5; 3<µ(S:N)<10; µ(S:N)<2.5 for respective cases. ‘µ(S:N)’ denotes mean normalized S:N
ratio values (i.e. the average normalized S:N ratio values fall within the range). Alternate
hypotheses: The average S: N ratio values do not fall within the given range. P value <0.05 rejects
the null hypothesis in favor of the alternate, whereas larger p values fail to reject the null
hypotheses.
Average normalized
Normalized S:N ratio value Null
pCases
S:N ratio value (AU)
Standard Deviation (AU)
Hypothesis
value
Eu3+ doped 4.34 (Europium filter)
1.26
3<µ(S:N)<7.5 >0.05
NP
1.01 (Rhodamine filter)
0.24
µ(S:N)<2.5
>0.05
6.41 (Rhodamine filter)
3.25
3< µ(S:N)<10 >0.05
EthD-1
1.58 (Europium filter)
0.83
µ(S:N)<2.5
>0.05
Other filters
Terbium
1.63
0.37
µ(S:N)<2.5
>0.05
filter
FITC
1.03
0.53
µ(S:N)<2.5
>0.05
filter
2.4 Conclusions
The combination of tumor heterogeneity and molecularly-targeted therapeutics has led to
a more personalized approach to medicine with the potential for individualized, combinatorial
therapeutics. However, for these treatment protocols to be effective, clinicians need highthroughput screening technologies capable of rapid and facile single cell analysis of an entire
patient sample. Techniques that can perform ex vivo quantification on the efficacy of drug doses
and combinations will greatly reduce the time between diagnosis and treatment of patients
suffering from cancer. As one such technique, this work proposes a novel nanoparticlemicrofluidic platform capable of high-throughput single cell analysis across a population of cells
challenged with different doses and combinations of chemotherapeutics. This was accomplished
by implementing biologically inert, rare earth (RE)-doped luminescent nanoparticles in a
microfluidic droplet trapping array to act as droplet trackers by visually isolating cancer cells
challenged with a specific dose.
Upon synthesis and spectral characterization, these RE-doped luminescent nanoparticles
were successfully proven to be biologically benign to living cancer cells through a series of offchip viability tests. As a proof-of-concept, Eu3+-doped nanoparticles were successfully
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encapsulated within droplets and a distinct emission spectrum in the red region was observed upon
encapsulation. The effect of dopant concentration (Eu3+: 2.5 mol% and 5 mol%) and NP slurry
concentration (5 mg/mL and 10 mg/mL) in NP encapsulation was analyzed to identify optimal
experimental conditions in terms of fluorescent signal intensity. This successful demonstration of
droplet tracking was further extended to track cells within droplets on a high-throughput droplet
microfluidic platform. A series of successful droplet trapping experiments co-encapsulating Eu3+doped NPs and GFP-expressing HeLa cells/ RFP-expressing MDA-MB-231 cells/ EthD-1-stained
dead MDA-MB-231 were performed. These experiments found that the RE-doped NP exhibited a
differing emission spectrum than common fluorophores (GFP, RFP) and fluorescent stains (EthD1). As an example, the spectral independence property of Eu3+ doped NP was quantified by a series
of line-scan ROI quantification and statistical analyses. These fluorescent signals from Eu3+ -doped
NP, GFP, RFP and EthD-1 were thus normalized, tabulated and verified for spectral independence
through a series of ANOVA-F-tests. As a result of this robust quantification and statistical
analyses, the spectral independence of these RE-doped nanoparticles was well ascertained. These
experimentation and analyses will be extended to Tb3+ doped NPs in the near future. Thus, this
work has demonstrated an innovative way of implementing these biologically inert and spectrally
independent RE- doped luminescent nanoparticles as droplet trackers on a high-throughput
microfluidic droplet trapping platform. While the studies described here only look at a single input
condition into the device, the system can easily be multiplexed by fabricating a three-, four-, or
five-input microfluidic droplet trapping array. In this new multiplexed system, the RE-doped NPs
can be used to visually distinguish different input conditions creating a platform to tandemly
screening different combinations of drugs across a population of cells. A further strength of this
system is that it is capable of performing both population-based and single-cell analysis of the
cancer cells to identify distinct subpopulations of cells, including drug resistant ones.
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3. AUTOMATED IMAGE ANALYSIS OF FLUORESCENT MICROSCOPY DATA
OBTAINED USING A DROPLET MICROFLUIDIC DEVICE
3.1 Introduction
Microscale technologies such as droplet microfluidics has garnered significant interest to
facilitate high-throughput, single cell analysis of heterogeneous populations like tumor biopsies.
The inclusion of downstream trapping arrays in these devices allow for facile collection and
segregation of droplets containing both single cells and multiple cells. The increasing number of
high-throughput technologies have created a need to develop computational tools capable of
processing and quantifying the large amount of data collected from these high-throughput screens.
Manual cell counting has been widely used; however, these results may be subjective and vary
from person to person. This resulted from the lack of software support for these techniques which
has made it difficult to apply open-source software packages with high-throughput technologies.
Existing open-source software like ImageJ[25] (NIH) and CellProfiler[26] (Broad Institute) are only
capable of counting the total number of cells in a defined region which is not suitable for
intracellular quantification on a large scale such as microfluidic trapping array. Proprietary
microarray software such as Quantarray (Packard BioChip Technologies, Billerica, MA, USA)
and Genepix (Molecular Devices, Sunnyvale, CA, USA) allow users to define arrays individually
on one image, but fail to recognize the arrays themselves automatically.[28] The goal of this work
was to develop an algorithm to rapidly analyze images of fluorescent cells trapping in droplets
collected in the microfluidic droplet trapping array that was capable of (i) automatically
distinguishing droplets from cells, (ii) counting live/dead cells in each droplet, and (iii) quantifying
variations in intracellular fluorescence due to cell permeable biosensor. As a proof of concept, the
algorithm was used to quantify two different systems. The first system was to quantify the
heterogeneous uptake of cell penetrating peptides across a population of cancer cells. Cell
penetrating peptides have emerged as powerful tools for delivering different types of bioactive
cargoes into the cytosol of intact cells for therapeutic and sensing purposes. However, the uptake
dynamics at the single cell level has never been assessed due the lack of available technologies.
Here, the algorithm will be used to analyze data collected by Safabakhsh et al[49] on CPP uptake.
Second, the algorithm will be used to distinguish between live and dead cells in a population of
MDA-MB-231 cells. The strength of the algorithm will show its ability to distinguish between the
cells, droplets and allow for facile counting of live and dead cells trapped in the droplets.
The algorithm called FluoroCellTrack was developed using the Python 2.7.5 software
language (Python Imaging Library, Python Software Foundation). The algorithm was designed to
handle overlay images obtained using fluorescent microscopy which consisted of both bright field
and fluorescence overlays. The advantage of using Python for this analysis was that, it is a highlevel, interpreted and general-purpose dynamic programming language which involves imperative
and simple object-oriented functional programming unlike the complex MATLAB scripts.
Moreover, the syntax in Python helps the programmers to code in a fewer steps as compared to
C++ or Java. The FluoroCellTrack algorithm was found to be able to (i) automatically identify
individual cells from cell clusters, (ii) detect single or multiple cells within a single droplet, and
(iii) quantify variations in intracellular fluorescence due to either CPP uptake or the incorporation
of live/dead stains. FluoroCellTrack takes <1 min to count cells and <7 mins to quantify
intracellular fluorescence, compared to ~60 min and ~20 h using manual analysis. The accuracy
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of FluoroCellTrack was compared with manual counting of cells and found a difference in only
~6 cells out of a total population of 320 cells leading to a 98% similarity between the two
approaches coupled with a 19-fold increase in analysis speed over manual counting. This algorithm
can potentially be used for dynamic cell viability studies, droplet tracking and biomarking
technologies.
3.2 Description of the Theory and Workflow used in the Development of the FluoroCellTrack
Algorithm for Automated Image Analysis
The details and methods describing the culturing of cell lines, the design and fabrication of
the microfluidic droplet trapping array are described in Chapters 2.2.3, 2.2.4. First set of data was
similar in scope to the results obtained from Chapter 2.3.4, where the mixed populations of live
and dead triple negative MDA-MB-231 cells were treated with Calcein AM and EthD-1 followed
by encapsulation into the aqueous droplets (without NP). The working of Calcein AM and EthD1 are described in Chapter 2.2.5. Quantifying data from this experiment was useful as it was similar
to quantifying a dynamic cell response (cell viability) on drug treatment protocols. The second set
of data was from a new experiment involving single cell analysis of CPP uptake in HeLa cells.
The same method was used for cellular encapsulation and analysis as those described for
quantifying dead staining in cells discussed in Chapter 2.3.4. Further details on methods performed
for CPP quantification can be found in Safabakhsh et. al.[49]

Figure 3.1 - Schematic of the multi-step python algorithm. A series of steps describing droplet and
cell template generation, template matching, thresholding leading to droplet and cell detection. A
final masking step resulting in the detection of number of cells per droplet.
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Once the data set of CPP uptake in a population of cells was collected, it was processed by
the FluoroCellTrack algorithm. The workflow for this is summarized in Figure 3.1, which
highlights the key steps needed to individually quantify viability in a high-throughput manner
across all of the cells trapped within the droplets. Prior studies by Khademhosseini et al. [27] and
Shusheng Bi et al.[48] were instrumental in the development of the FluoroCellTrack algorithm. For
the analysis, overlay images (~75-80 images) from each encapsulation experiment obtained using
fluorescent microscopy were used as input. These overlay images, which consisted of both
brightfield and fluorescence overlays, were batch-fed into the algorithm for analysis. The imaging
features of this multi-step python algorithm such as droplet detection and cell detection are
described for an example image (i of Figure 3.1) in this section.
Droplet detection
The overlay image as shown in (i) of Figure 3.1, had information about droplets (in
brightfield) and cells (fluorescent red for dead cells, fluorescent green for live cells). This input
overlay image was subjected to thresholding to enhance the dark features in the brightfield channel
(e.g., the droplet outline) as a result of which, the outlines of droplets were highlighted to give
image (step ii) of Figure 3.1, which was given a name D. After this step, template matching was
performed to detect droplets. To do this, a droplet template (step v of Figure 3.1) was generated as
a starting point. This droplet template was given a name, dw. Droplet template matching was done
by convolving the droplet template dw with the initial thresholded image D to generate a droplet
center correlation map Cd as shown in Eq 3.1. Template matching is a process where a template
defined by the user (user-defined template) slides over the image pixel by pixel to find the objects
in the image that are most similar to the template.
Cd=D*dw

[Eq 3.1]

The brighter pixels in this droplet center correlation map depicted the highly correlated points
which were most likely to be the droplet centers. To precisely locate the droplet centers and remove
the false positives, the local maxima in the droplet center correlation map were found using Eq 3.2
to give droplet local maxima image Ld (image not shown) as shown below:
Ld=l(Cd,Wd)

[Eq 3.2]

where l is a smoothing function done to the droplet center correlation map Cd to locate the local
maxima of droplet centers with Wd as the window size used to search for the local maxima. Smaller
window sizes were used for more precise local maxima location. This local maxima image Ld was
further thresholded to generate the droplet center image Md (step vii of Figure 3.1) as shown in Eq
3.3.
Md=T(Ld,τd)

[Eq 3.3]

where T is the thresholding function used to generate the droplet center image Md containing the
thresholded local maxima of droplet centers with values greater than the threshold value τd. This
threshold value τd was selected appropriately to minimize misdetections and false positives. As a
final step, droplet circles were drawn using the previously obtained droplet center image Md and
known diameter range of 65-75 pixels. This range of droplet diameter was picked due to the slight
variability seen in droplet sizes obtained after encapsulation experiments. For example, the input
image in (step i) of Figure 3.1 had a resolution of 679 pixels (length) x 376 pixels (width), with
droplet diameter of 70 pixels, as a result of which the final droplet map was generated as shown in
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(step x) of Figure 3.1. This final step was elaborately used for cell detection which is described in
the following paragraphs.
Live/dead cell detection
Cell detection consisted of similar steps explained in the previous section like template
generation, template matching, center localization and thresholding. In addition to this, one final
step was added to count the number of cells within each droplet. This live/dead cell detection
algorithm is described using an example image (step i of Figure 3.1) in this section. As a starting
point, the overlay image as shown in (step i) of Figure 3.1, which had information about droplets
(in brightfield) and cells (fluorescent red for dead cells, fluorescent green for live cells) was used
as an input. This input overlay image was a color image and it was used as an advantage to be split
into red, green, blue (RGB) channels. As a result of this channel splitting, G and R were obtained
as resultant images: G is the grayscale image of green channel representing live cells (step iii of
Figure 3.1) and R is the grayscale image of red channel representing dead cells (step iv of Figure
3.1). After this step, template matching was performed to detect cells. To do this, a cell template
(step vi of Figure 3.1) was generated by the user. This cell template was given a name, cg/r. Cell
template matching was done by convolving the cell template cg/r with the grayscale green and red
channel images G and R, to generate live and dead cell center correlation maps Cg and Cr as shown
in Eq 3.4.
Cg and Cr = (G and R) *cg/r

[Eq 3.4]

The brighter pixels in these center correlation maps depicted the highly correlated points which
were most likely to be the live and dead cell centers. To locate the cell centers and remove the
false positives, the local maxima in the live and dead correlation maps were found using Eq 3.5 to
give the live cell and dead cell local maxima images Lg and Lr (images not shown) as shown below:
Lg and Lr = l(Cg and Cr, Wg/r)

[Eq 3.5]

where l is a smoothing function done to the live and dead center correlation maps Cg and Cr to
locate the local maxima of live/dead cell centers with Wg/r as the window size used to search for
the local maxima. Smaller window sizes were used for more precise local maxima location. These
local maxima images Lg and Lr were further thresholded to generate the live and dead cell center
images Mg and Mr (steps viii and ix of Figure 3.1) as shown in Eq 3.6.
Mg and Mr=T(Lg and Lr, τg/r)

[Eq 3.6]

where T is the thresholding function used to generate the final live and dead cell center images Mg
and Mr containing the thresholded local maxima of cell centers with values greater than the
threshold value τg/r. This threshold value τg/r was selected appropriately to minimize misdetections
and false positives. Such a thresholding step helped in identifying individual cells in clusters. One
final step was added here in order to count the number of live and dead cells within each droplet.
For this, the final droplet map obtained as shown in (step x) of Figure 3.1 was masked individually
over the final live and dead cell center images (steps viii and ix of Figure 3.1) to count the number
of live and dead cells within each droplet. While masking the droplet map on a combined live/dead
cell center images, gives information on single/multiple cell encapsulation count as shown in (step
xi) of Figure 3.1. For example, by defining the droplet diameter range and masking the combined
live/dead cell center maps, if two cell centers were detected within a droplet boundary, then it
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would be considered as two cells per droplet. The quantified results of cell viability count and cell
encapsulation count were exported separately to excel sheets for further analysis.
Intercellular fluorescence level detection
The algorithm was extended to quantify the heterogeneous uptake of cell penetrating
peptides across a population of cancer cells. These cell penetrating peptides have emerged as
powerful tools for delivering different types of bioactive cargoes into the cytosol of intact cells for
therapeutic and sensing purposes, but the uptake dynamics at the single cell level has never been
assessed due the lack of available technologies. Data collected by Safabakhsh et al[49] on CPP
uptake was used for quantification, where the cell permeability of secondary structured β-hairpin
cell penetrating peptides like RWRWR [Ac-RWVRVpGO(FAM)WIRQNH2], OWRWR [AcOWVRVpGO(FAM)WIRQNH2] was compared with that of commercially available fluorescent
peptides (Arginine and TAT) in terms of fluorescent intensity in single cancer cells by using the
droplet microfluidic array. The fluorescent signal was due to the FAM tag attached to the peptide
and this fluorescent intensity was measured using a fluorescent microscopy FITC with excitation
and emission range of 490 nm and 535 nm. This CPP uptake was examined in model cancer cells
including cervical cancer-derived HeLa cells, multiple myeloma-derived OPM2 cells. The
fluorescent microscopy data (~75 to 80 images) from each encapsulation experiment consisting
information of varying fluorescent intensity from cells (corresponding to the varying cell
permeability of different peptides) was quantifying using FluoroCellTrack as shown in Figure 3.2.

Figure 3.2 - Schematic of the Python algorithm to quantify cell data. Brightfield and fluorescent
images were input into the algorithm to define droplets and cells followed by template matching
to identify single cells and measure cellular fluorescence
Here, the fluorescent intensity quantification of an example image from a cell permeability
and encapsulation experiment of 10 µM Arginine in single HeLa cells is described. As a starting
point, the overlay image as shown in (step i) of Figure 3.2, which had information about droplets
(in brightfield) and cells (fluorescent green for peptide uptake) was used as an input. The steps
described in droplet detection were used to detect droplets. For cell detection, the steps described
in live/dead cell detection were used. However, it is to be noted here that, after splitting the overlay
image, only the green channel produced information corresponding to the fluorescent peptide
uptake within cells (step ii in Figure 3.2). This was due to the fact that the FAM tag of these CPPs
upon entering the cells emitted in the green region. After a series of cell template generation and
cell template matching to detect cells, a step was included here to generate regions of interest
(ROI’s) around the detected cell blobs as shown in (step iii) of Figure 3.2. Upon generation of
ROI’s around the cells, maximum and mean pixel intensity values within each ROI, corresponding
to the maximum and minimum fluorescent intensity were generated. These quantified values lied
in the range of 0-255: 0 meaning no fluorescence (no CPP uptake) with 255 denoting maximum
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fluorescence (maximum CPP uptake). Appropriate threshold values were used during this step to
clearly eliminate false positives such as high background or false signal from peptide debris. In
addition to the above-mentioned quantification of fluorescent intensities, areas of these ROI’s were
detected and appropriately thresholded to eliminate false positives by distinguishing cells from
debris. For example, a typical HeLa cell in each permeability and encapsulation experiment had a
diameter of 20 pixels (corresponding to 20 microns). This was used as an advantage to eliminate
several peptide debris which had diameters less than 20 pixels, thus eliminating false signals. The
quantified fluorescent intensities with respective ROI area were finally exported to excel for
further data analysis.
3.3 Results and Discussion
Successful quantification of cell count and viability in single and multiple cells using
FluoroCellTrack
The data obtained from the live/dead experiments described in Chapter 2.3.4 was
quantified here using the microfluidic device and the FluoroCellTrack algorithm. The difference
here was that, the mixed subpopulation of live and dead triple negative MDA-MB-231 cells were
treated with both Calcein AM and EthD-1 prior to encapsulation within the droplets (without NP).
Quantifying data from this experiment gave information about the number of live cells, the number
of dead cells and the single vs. multiple cell encapsulation efficiencies.

Figure 3.3 – Quantification of cell viability and single/multiple cell per droplet information.
Overlay image (A) of brightfield and fluorescent (red and green) channels was used an input to be
quantified by FluoroCellTrack through a series of droplet, cell detection and masking steps to
detect single/multiple live and dead cells within droplets (B)
The overlay images (~76 images) from the live/dead staining and encapsulation experiment
of MDA-MB-231 cells were successfully quantified with the algorithm. For the sake of brevity,
this section will discuss one representative image from this data set. As seen in Figure 3.3, the
input overlay image was successfully quantified for the number of live and dead cells along with
the total single cell count. The droplet and cell detection steps as described in Chapter 3.2 were
successfully able to detect droplets and cells. Further, defining droplet boundaries and masking of
these droplet circles over the detected cells successfully gave the single/multiple live and dead cell
count. The example excel data that was exported after quantification of this Figure 3.3.A is shown
in Table 3.1.
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Table 3.1 – Quantification of cell count and viability data of single/multiple cell encapsulation
No. of droplets with single cells - 2
No. of droplets with multiple cells - 1
Droplet No. of live cells No. of dead cells Total cells
1
2
3
1
1
4
1
1
5
1
2
3
6
7
Quantification of intercellular fluorescence intensity representative of CPP uptake using
FluoroCellTrack
Permeability of several cell penetrating peptides like RWRWR, OWRWR, Arginine and
TAT were quantified based on fluorescent intensity using this algorithm. The resultant
quantification of one example image (out of 79 images) from an encapsulation experiment of 10
µM Arginine in single HeLa cells is discussed here. As a result of this quantification, the
permeability of the peptide Arginine was measured across a population of HeLa cells based on
fluorescent intensity. The droplets and cells were successfully detected using the initial droplet
and cell detection steps. After this step, ROI’s were successfully generated around the detected
cells as shown in Figure 3.4. The maximum and mean fluorescent intensity values (in the range of
0-255) of these ROI’s of detected cell blobs were successfully quantified. Moreover, these ROI’s
were utilized to successfully distinguish cells from debris which eliminated false positive signals
from peptide and cellular debris. The example data output file from quantification of Figure 3.4.A
is shown in Table 3.2. For further data analysis, these quantified fluorescent intensity values were
compared to background to give normalized S: N values. The quantified data of all the 79 images
from this 10µM arginine uptake experiment is given in Table A.1 in Appendix.

Figure 3.4 – Quantification of 10 µM arginine uptake in HeLa cells based on fluorescent intensity.
Overlay image of brightfield and fluorescent (green) channel (A) was used as input to be quantified
by FluorCellTrack through a series of droplet, cell detection and ROI generation to identify cells
and measure mean/maximum cellular fluorescence intensity.
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Table 3.2 – Quantification of 10 µM arginine uptake in HeLa cells based on fluorescent intensity
No. of droplets with single cells - 4
No. of droplets with multiple cells - 0
Area (pixel
Max. fluorescent intensity
Mean fluorescent intensity
ROI
square)
(pixel)
(pixel)
ROI1
681.50
243.78
200.40
ROI2
542.81
250.42
213.08
ROI3
904.26
213.84
209.36
ROI4
1008.41
232.02
212.68
Comparison between manual cell counting and FluoroCellTrack
To compare the automated counting results with the manual ones, all 76 images (step i of
Figure 3.1) from the previously explained live/dead staining experiment of MDA-M-231 cells
were subjected to manual and automated quantification. The data was compared for droplet
trapping efficiency, single/multiple cell encapsulation, empty droplets and live/dead cell count. As
depicted in Figure 3.5, the graphs representing automated and manual counting are almost
identical, which shows that the two counting approaches are analogous to each other. However,
there was a difference ~ of 6 to 7 multiple cells which were considered as single cells out of a
population of ~180 cells, during automated quantification. This was due to the fact that despite
precise thresholding, single cells could be shadowed within multiple cell clusters across the
trapping array. Such false positives were of very negligible fractions and thus were eventually
neglected. Further, the analysis speeds of automated and manual counting were compared.
FluoroCellTrack took <1 min to count cells and <10 mins to quantify intracellular fluorescence
intensity on a typical 2.4 GHz processor. The process time of 10 mins consisted of the time
fractions spent on droplet, cell segmentation and detection, cell counting and fluorescence intensity
measurements. This was superior to the ~60 min cell counting and ~20 h of fluorescence
quantification using manual analysis. This algorithm had 98% similarity with manual counting and
a 19-fold increase in analysis speed.

Figure 3.5 – Comparison of automated image analysis (Python algorithm) with manual counting
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3.4 Conclusions
The multistep Python algorithm, FluoroCellTrack was developed to process and analyze
hundreds of microscope images collected during experimentation. The algorithm had several
distinct features like automatic detection of droplet subpopulations such as empty droplets, single
or multiple cells inside droplets, etc. The proposed algorithm was successfully implemented in two
different systems: (i) live/dead subpopulation studies to understand cell viability and count the
number of single/multiple cells within each droplet, (ii) quantification of permeability of different
CPPs in single cells based on fluorescent intensity. This algorithm had well-defined and precise
steps to eliminate false positives such as peptide and PDMS debris across trapping array. Manual
control analyses conformed with the Python algorithm with a difference of just about ~6 to 7 cells
(98% similarity). Moreover, this automated image analysis took about <1 min to count all the cells
trapped in the array and <10 min to quantify the fluorescence intensity across the entire population
of cells, proving it to be a powerful tool for microscopy data analysis. This was far superior to the
~60 min cell counting and ~20 h of fluorescence quantification using manual analysis. Thus, the
proposed algorithm could automatically identify individual cells from clusters, count single or
multiple live/dead cells per droplet and thus can potentially be used for quantifying dynamic cell
viability and droplet tracking experimentation as described in Chapters 2.3.4.
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4. SUMMARY, CONCLUSIONS AND FUTURE WORK
4.1 Summary
Molecularly-targeted therapeutics and personalized medicine have dramatically increased
the prognosis of patients suffering from cancer. However, tumor heterogeneity has limited the
success of single drug treatment which led to the introduction of multiple therapeutic
combinations. As such, multiple therapeutic combinations have required the development of new
analytical methods capable of multiplexed high-throughput screening (HTS) technologies capable
of examining both concentration and number of therapeutics. Droplet microfluidic devices have
garnered significant interest to facilitate high-throughput, single cell analysis. One limitation of
droplet generators is their ability to only assess a single input conditions like concentration or
number of drugs. To address this limitation, rare earth (RE)-doped nanoparticles were coupled
with a microfluidic droplet trapping array as a novel approach at droplet tracking to visually assess
different input conditions into the device such as drug doses and combinations in the droplets. The
β-hexagonal NaYF4 nanoparticles were doped with rare-earth emitters (Eu3+ and Tb3+) which have
a luminescence emission spectrum in the red and green region upon UV excitation. An advantage
of the RE-doped nanoparticles is that their excitation and emission spectra do not overlap with
standard fluorophores thus allowing for both droplet tracking and quantification of cell viability
or enzyme activity. This spectral independence was observed in (i) GFP-expressing HeLa cell, (ii)
RFP-expressing MDA-MB-231 cells, and (iii) pre-killed MDA-MB-231 cells stained with
ethidium homodimer-1. Moreover, the RE-doped nanoparticles were confirmed to be biologically
inert. Finally, a Python algorithm was developed to automatically distinguish droplets from cells,
count cells in each droplet, and quantify cell viability to facilitate the single cell analysis in a highthroughput manner. Thus, this work established the foundation for future applications using this
technique in multiplexed droplet tracking to understand tumor heterogeneity through
combinatorial therapies. The applications for this algorithm are numerous including fluorescence
quantification, droplet tracking, and biomarker detection.
4.2 Conclusions
The droplet microfluidic trapping array described in this thesis is similar in design to one
previously reported by Safabakhsh et al[49] described in Section 2.2.3. This device was successfully
tested for its potential to isolate and trap single cancer cells in a high-throughput manner. To extend
the application of this droplet microfluidic device in droplet tracking, a library of RE-doped βNaYF4 luminescent nanoparticles was synthesized by a hydrothermal process. These nanoparticles
were further successfully characterized for structure, morphology and optical properties using
Scanning Electron Microscopy (SEM), X-Ray Diffraction (XRD), Energy-dispersive X-ray
spectroscopy and Photoluminescence tests (PL). As observed in Figure 2.3, the SEM analysis
showed hexagonal nanoparticles roughly 150 nm in diameter and 400 nm in length. The XRD scan
and EDX fluorescence resulted in hexagonal β-NaYF4 crystal structures without the presence of
contaminates. Photoluminescence of Eu3+ and Tb3+ doped NaYF4 nanoparticles demonstrated the
characteristic red (for Europium) and green (for Terbium) emission peaks when excited with UV
light. Further from Figure 2.4, it was seen that these nanoparticles were biologically inert in the
triple negative breast cancer cell line MDA-MB-231 for a period of 12 h indicating their ability to
be used on-chip with biological systems for long-term dynamic experiments. The novelty of this
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work lies in the usage of RE-doped nanoparticles in fluorescent microscopy. As a proof-ofconcept, Eu3+-doped nanoparticles were successfully encapsulated within droplets and a distinct
emission spectrum in the red region was observed upon encapsulation (Figure 2.6). The effect of
dopant concentration (Eu3+: 2.5 mol% and 5 mol%) and NP slurry concentration (5 mg/mL and 10
mg/mL) in NP encapsulation was analyzed (Tables 2.1 and 2.2) to identify optimal experimental
conditions in terms of fluorescent signal intensity. This successful demonstration of droplet
tracking was further extended to track cells within droplets on a high-throughput droplet
microfluidic platform. A series of successful droplet trapping experiments co-encapsulating Eu3+doped NPs and GFP-expressing HeLa cells/ RFP-expressing MDA-MB-231 cells/ EthD-1-stained
dead MDA-MB-231 were performed as shown in Figures 2.7 and 2.8. These experiments found
that the RE-doped NP exhibited a differing emission spectrum than common fluorophores (GFP,
RFP) and fluorescent stains (EthD-1). As an example, the spectral independence property of Eu3+
doped NP was quantified by a series of line-scan region of interest (ROI) quantification and
statistical analyses (Tables 2.3 to 2.5). The fluorescent signals from Eu3+-doped NPs, GFPexpressing cells, RFP-expressing cells and EthD-1-stained cells were normalized, tabulated and
verified for spectral independence through a series of ANOVA-F-tests as shown in Tables 2.7 to
2.9. As a result of this robust quantification and statistical analyses, the spectral independence of
these RE-doped nanoparticles was well ascertained. The overall high-throughput of these
experiments were further increased by automating the image analysis. To account for the highly
subjective and laborious manual counting, a multistep Python algorithm (Figures 3.1, 3.2)
involving (i) droplet and cell template matching, (ii) cell center mapping, and (iii) local maxima
and thresholding was developed to quantify droplet trapping efficiency, cell encapsulation
efficiency, cell viability, and intracellular fluorescence intensity. This automated analysis was
found to be accurate with manual counting of cells, with a difference of just ~2% coupled with a
decrease in analysis time of <10 minutes over 20 hours of manual analysis.
4.3 Future Work
The goal of the future work is to increase the overall throughput of the combined
nanoparticle-microfluidic approach by expanding upon the capabilities of the microfluidic droplet
trapping array and the RE-doped nanoparticles. The studies described in this work looked at a
single input condition into the microfluidic device; however, the system can easily be multiplexed
by fabricating three-, four-, or five-input microfluidic droplet trapping arrays for increased
throughput. The next step is to incorporate two additional flow focusing junctions into the
microfluidic device to allow for simultaneous generation and trapping of aqueous droplets from
three different inputs. This multiplex platform will be extended to screen different combinations
of drugs across a population of cells. For this, the three distinct types of RE-doped nanoparticles
(europium doped NPs along with terbium and dysprosium doped NPs) will be used. The distinct
emission spectra of Eu3+-doped NPs in the red spectrum, Tb3+-doped NPs in the green spectrum,
and Dy3+-doped NPs in the blue spectrum will be utilized to track and visually distinguish cells
within aqueous droplets and finally allow for evaluation of three different treatment protocols in
the same device (Figure 4.1).The dysprosium doped nanoparticles along with europium and
terbium doped nanoparticles will be characterized for the correct structure, morphology,
biocompatibility and downconversion application in fluorescent microscopy as described in
Chapter 2. Terbium and dysprosium nanoparticles will be individually co-encapsulated with
model cancer cells like GFP HeLa cells, RFP MDA-MB-231 cells, dead MDA-MB-231 cells to
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test their potential as droplet trackers (similar to Section 2.3.4). Their spectral independence with
the commonly found fluorophores and fluorescent stains like GFP, RFP and ethidium homodimer
will further be quantified and statistically analyzed as described in Section 2.3.5. Upon successful
characterization of terbium and dysprosium for on-chip droplet tracking, the three distinct REdoped NPs will be incorporated into the three-input microfluidic device to encapsulate, trap and
visually distinguish three subpopulations of cells. Further, multiple myeloma OPM2 cells will be
challenged with three different orders of magnitude of the proteasome inhibitor bortezomib (1, 10,
and 100 nM) and will be monitored across the high-throughput multi-input droplet tracking system
to characterize drug efficacy and the dynamic response of cancer cells to multiple therapeutics,
potentially identifying drug resistant cells. The automated image analysis described in Chapter 3
will be utilized to quantify the results for the multiplexed NP-cell co-encapsulation experiments.
Such a multiplexed system involves three distinct nanoparticles tracking three different treatment
protocols in the form of cell viability. For this, the microscopy images from these multiplexed
experiments will be processed to assign different colors for different species such as: red color for
dead cell, cyan color for terbium nanoparticle, magenta color for europium nanoparticle and yellow
color for dysprosium nanoparticle. The initial overlay microscopy images will be split into Red,
Green, Blue channels (R channel giving information about dead cells), and Cyan, Magenta,
Yellow, Black channels (C, M, Y, K channels) to give information about the presence of respective
nanoparticles in droplets. These images will be used to (i) detect NP tracking efficiency, (ii) cell
viability within the droplet, and (iii) cell and nanoparticle template matching. Droplet, cell, and
NP cluster center correlation maps will be obtained after performing local maxima and
thresholding steps similar to Section 3.2. Thus, overlapping the resultant center maps will give
information on three distinct subpopulations based on cell response (viability) to different drug
treatment protocols.

Figure 4.1 – Schematic of the multi-input droplet microfluidic trapping array shown from the top.
Graphic depicts Eu3+-doped (red), Dy3+-doped (blue), and Tb3+-doped (green) nanoparticles
encapsulated with cells treated with different doses of chemotherapeutics. Droplets will be isolated
in a trapping array downstream of the three junctions (dashed box). Grey is PDMS and yellow is
the carrier oil.
Moreover, this novel nanoparticle-microfluidic platform will be further extended to
understand the efficacy of molecularly-targeted therapeutics by precisely quantifying the enzyme
activity of critical oncogenic pathway of ubiquitin proteasome system (UPS) in model cancer cells.
Proteasome and deubiquitinating enzymes (DUBs) are the primary targets from UPS due to the
clinical success of proteasome inhibitors and recent findings confirming the role of DUBs in
multiple myeloma cells developing a resistance to these proteasome inhibitors. The quantification
of intracellular enzyme activity in intact single cells across a population of cells like a liquid biopsy
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would be beneficial to determine how patients respond to proteasome-targeted therapies, and to
identify distinct subpopulations of drug-resistant cells in a heterogeneous sample. This will be
achieved by developing a new method to directly measure enzyme activity in intact single cells
across a heterogeneous population. This will be accomplished by developing unique fluorescent
proteasome reporters that are long-lived, cell permeable, and enzyme-specific that incorporate a
primary degron (peptide motif that specifies substrate recognition by E3 ubiquitin ligases) that is
ubiquitinated in cells and also functions as a cell penetrating peptide. The substrate is a β-hairpin
‘protectide’ sequence that will be incorporated into a novel fluorescence resonance energy transfer
(FRET) reporter to directly quantify proteasome activity in intact cells. This novel proteasome
reporter will be coupled with a novel DUB reporter developed by our research group to achieve
multiplexed detection of two enzymatic targets. To achieve high throughput screening, the reporter
will be incorporated in the droplet microfluidic trapping array capable of encapsulating and
isolating single cells followed by dynamic quantification of intracellular enzyme activity. This
technique will incorporate the rare-earth (RE)-doped luminescent nanoparticles in the multiplexed
droplet microfluidic device for droplet tracking to correspond to different input conditions to
increase the overall throughput of the system. The throughput will further be increased by
automating the measurement of heterogeneous enzyme activity in single cells by quantifying the
varying fluorescent intensity across the population. This bioanalytical tool will account for the
significant heterogeneity associated with tumor biopsies and identifies distinct subpopulations of
cells, including low-frequency, drug-resistant cells.
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APPENDIX
Table A.1 – Heterogenous fluorescence intensity of 10 µM Arginine uptake in HeLa cells.
Quantified data giving information on single/multiple cell encapsulation. Each ROI represents
HeLa cells with its corresponding fluorescence intensity
Single cell count
58
Multiple cell count
ROI
FLUORESCENCE INTENSITY (AU)
ROI1 178.83
ROI2 212.49
ROI3 169.13
ROI4 153.02
ROI5 204.57
ROI6 174.32
ROI7 100.34
ROI8 89.98
ROI9 217.94
ROI10 224.12
ROI11 210.85
ROI12 183.63
ROI13 163.14
ROI14 90.62
ROI15 200.98
ROI16 239.74
ROI17 215.61
ROI18 242.93
ROI19 200.44
ROI20 172.39
ROI21 230.82
ROI22 100.76
ROI23 209.17
ROI24 196.58
ROI25 80.64
ROI26 200.32
ROI27 216.18
ROI28 183.82
ROI29 176.99
ROI30 234.65
ROI31 119.59
ROI32 187.36
ROI33 200.51
ROI34 214.12
ROI35 164.93
ROI36 167.26
ROI37 188.72
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13
NOISE (AU)
9.77
9.77
9.77
8.2
8.2
8.2
8.2
8.2
15.23
15.23
15.23
15.23
6.95
6.95
6.95
6.95
7.81
7.81
7.81
7.81
7.81
7.98
7.98
7.98
7.98
9.42
9.42
9.42
9.42
8.66
8.66
8.66
8.66
9.41
9.41
9.41
9.41

ROI38
ROI39
ROI40
ROI41
ROI42
ROI43
ROI44
ROI45
ROI46
ROI47
ROI48
ROI49
ROI50
ROI51
ROI52
ROI53
ROI54
ROI55
ROI56
ROI57
ROI58
ROI59
ROI60
ROI61
ROI62
ROI63
ROI64
ROI65
ROI66
ROI67
ROI68
ROI69
ROI70
ROI71
ROI72
ROI73
ROI74
ROI75
ROI76
ROI77
ROI78
ROI79
ROI80
ROI81

194.58
218.61
105.49
185.38
153.73
249.03
194.28
243.84
128.42
220.37
196.75
230.49
159.9
213.12
184.93
191.19
167.33
242.73
214.61
188.41
199.49
200.36
167.42
100.94
163.2
199.05
164.06
190.37
203.84
172.43
222.93
172.04
118.33
170.26
186.95
200.21
214.35
204.82
226.04
173.95
177.52
188.67
250.81
138.94

9.41
9.41
7.29
7.29
7.29
7.29
8.04
8.04
10.82
10.82
10.82
8.3
8.3
8.3
8.3
9.71
9.71
9.71
11.55
11.55
11.55
11.55
9.09
9.09
9.09
9.09
9.09
8.24
8.24
8.24
8.24
9.56
9.56
12.95
12.95
10.28
8.46
8.46
8.46
9.43
9.43
8.27
8.27
9.18
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